Loading…
Reported covered position: NONE
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Newborn Screening Saves Lives Reauthorization Act of 2019
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
H.R. 2507: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2019; ALL PROVISIONS OF THE BILL H.R. 6238: CAMERON'S LAW; ALL PROVISIONS OF THE BILL S 2158: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2019; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING PRESCRIPTION DRUG PRICING AND GENE THERAPY GENERAL DISCUSSIONS REGARDING ORPHAN DRUG ACT
Newborn Screening Saves Lives Reauthorization Act of 2019
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2020 · second_quarter · Q2
H.R. 2507: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2019; ALL PROVISIONS OF THE BILL H.R. 4439: CREATING HOPE REAUTHORIZATION ACT; ALL PROVISIONS OF THE BILL S 2158: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2019; ALL PROVISIONS OF THE BILL S 4010: CREATING HOPE REAUTHORIZATION ACT; ALL PROVISIONS OF THE BILL CONTROLLED SUBSTANCE UTILIZATION REVIEW AND EVALUATION SYSTEM 2.0: GENERAL DISCUSSIONS REGARDING INNOVATION GENERAL DISCUSSIONS REGARDING GENE THERAPY AND OFFICE OF BIOTECHNOLOGY ACTIVITIES GENERAL DISCUSSIONS REGARDING ORPHAN DRUG ACT
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Source: Senate LDA
H.R. 2507: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2019; ALL PROVISIONS OF THE BILL H.R. 4439: CREATING HOPE REAUTHORIZATION ACT; ALL PROVISIONS OF THE BILL S 2158: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2019; ALL PROVISIONS OF THE BILL S 4010: CREATING HOPE REAUTHORIZATION ACT; ALL PROVISIONS OF THE BILL CONTROLLED SUBSTANCE UTILIZATION REVIEW AND EVALUATION SYSTEM 2.0: GENERAL DISCUSSIONS REGARDING INNOVATION GENERAL DISCUSSIONS REGARDING GENE THERAPY AND OFFICE OF BIOTECHNOLOGY ACTIVITIES GENERAL DISCUSSIONS REGARDING ORPHAN DRUG ACT
Creating Hope Reauthorization Act
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
H.R. 2507: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2019; ALL PROVISIONS OF THE BILL H.R. 4439: CREATING HOPE REAUTHORIZATION ACT; ALL PROVISIONS OF THE BILL S 2158: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2019; ALL PROVISIONS OF THE BILL S 4010: CREATING HOPE REAUTHORIZATION ACT; ALL PROVISIONS OF THE BILL CONTROLLED SUBSTANCE UTILIZATION REVIEW AND EVALUATION SYSTEM 2.0: GENERAL DISCUSSIONS REGARDING INNOVATION GENERAL DISCUSSIONS REGARDING GENE THERAPY AND OFFICE OF BIOTECHNOLOGY ACTIVITIES GENERAL DISCUSSIONS REGARDING ORPHAN DRUG ACT
H.R. 2507: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2019; ALL PROVISIONS OF THE BILL H.R. 6238: CAMERON'S LAW; ALL PROVISIONS OF THE BILL S 2158: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2019; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING PRESCRIPTION DRUG PRICING AND GENE THERAPY GENERAL DISCUSSIONS REGARDING ORPHAN DRUG ACT
The Newborn Screening Saves Lives Reauthorization Act of 2019
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
H.R. 2507: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2019; ALL PROVISIONS OF THE BILL H.R. 4439: CREATING HOPE REAUTHORIZATION ACT; ALL PROVISIONS OF THE BILL S 2158: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2019; ALL PROVISIONS OF THE BILL S 4010: CREATING HOPE REAUTHORIZATION ACT; ALL PROVISIONS OF THE BILL CONTROLLED SUBSTANCE UTILIZATION REVIEW AND EVALUATION SYSTEM 2.0: GENERAL DISCUSSIONS REGARDING INNOVATION GENERAL DISCUSSIONS REGARDING GENE THERAPY AND OFFICE OF BIOTECHNOLOGY ACTIVITIES GENERAL DISCUSSIONS REGARDING ORPHAN DRUG ACT
The Newborn Screening Saves Lives Reauthorization Act of 2019
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
H.R. 2507: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2019; ALL PROVISIONS OF THE BILL H.R. 6238: CAMERON'S LAW; ALL PROVISIONS OF THE BILL S 2158: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2019; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING PRESCRIPTION DRUG PRICING AND GENE THERAPY GENERAL DISCUSSIONS REGARDING ORPHAN DRUG ACT
Creating Hope Reauthorization Act
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
H.R. 2507: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2019; ALL PROVISIONS OF THE BILL H.R. 4439: CREATING HOPE REAUTHORIZATION ACT; ALL PROVISIONS OF THE BILL S 2158: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2019; ALL PROVISIONS OF THE BILL S 4010: CREATING HOPE REAUTHORIZATION ACT; ALL PROVISIONS OF THE BILL CONTROLLED SUBSTANCE UTILIZATION REVIEW AND EVALUATION SYSTEM 2.0: GENERAL DISCUSSIONS REGARDING INNOVATION GENERAL DISCUSSIONS REGARDING GENE THERAPY AND OFFICE OF BIOTECHNOLOGY ACTIVITIES GENERAL DISCUSSIONS REGARDING ORPHAN DRUG ACT
Medicare Negotiation and Competitive Licensing Act of 2019
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
H.RES. 242: AFFIRMING THE IMPORTANCE OF THE ORPHAN DRUG ACT, CELEBRATING THE OVER 750 NEW ORPHAN THERAPIES APPROVED SINCE ITS CREATION, AND RECOGNIZING THE NEED TO CONTINUE SUPPORTING RESEARCH AND DEVELOPMENT FOR RARE DISEASE; ALL PROVISIONS OF THE RESOLUTION H.R. 1046: MEDICARE NEGOTIATION AND COMPETITIVE LICENSING ACT OF 2019; ALL PROVISION OF THE BILL S. 377: MEDICARE NEGOTIATION AND COMPETITIVE LICENSING ACT OF 2019; ALL PROVISION OF THE BILL GENERAL DISCUSSIONS REGARDING GENE THERAPY AND VALUE BASED CONTRACTING GENERAL DISCUSSIONS REGARDING NEWBORN SCREENING RE-AUTHORIZATION ACT GENERAL DISCUSSIONS REGARDING THE ORPHAN DRUG ACT GENERAL DISCUSSIONS REGARDING HEALTH CARE FINANCING
H.R. 3: LOWER DRUG COSTS NOW ACT OF 2019; ALL PROVISIONS OF THE BILL H.R. 2069: SPIKE ACT; ALL PROVISIONS OF THE BILL H.R. 2296: MORE EFFICIENT TOOLS TO REALIZE INFORMATION FOR CONSUMERS ACT; ALL PROVISIONS OF THE BILL H.R. 2375: PRESERVE ACCESS TO AFFORDABLE GENERICS AND BIOSIMILARS ACT; ALL PROVISIONS OF THE BILL H.R. 2507: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2019; ALL PROVISIONS OF THE BILL H.R. 3235: ACCESS TO GENETIC COUNSELOR SERVICES ACT OF 2019; ALL PROVISIONS OF THE BILL H.R. 4439: CREATING HOPE REATHORIZATION ACT; ALL PROVISIONS OF THE BILL S. 2158: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2019; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING THE PRESCRIPTION DRUG PRICING REDUCTION ACT'S OUTCOMES BASED AGREEMENTS GENERAL DISCUSSIONS RELATED TO PHENYLKETONURIA (PKU) LOST TO FOLLOW UP
Prescription Drug STAR Act
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
H.R. 2113: PRESCRIPTION DRUG STAR ACT; ALL PROVISIONS OF THE BILL H.R. 2296: FAIR DRUG PRICING ACT OF 2019; ALL PROVISIONS OF THE BILL H.R. 2507: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2019; ALL PROVISIONS OF THE BILL S 474: STOPPING THE PHARMACEUTICAL INDUSTRY FROM KEEPING DRUGS EXPENSIVE (SPIKE) ACT OF 2019; ALL PROVISIONS OF THE BILL S. 1391 FAIR ACCOUNTABILITY AND INNOVATIVE RESEARCH (FAIR) DRUG PRICING ACT OF 2019; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING GENE THERAPY GENERAL DISCUSSIONS REGARDING THE ORPHAN DRUG ACT AND TAX CREDIT (NOT YET INTRODUCED) GENERAL DISCUSSIONS REGARDING PATIENT AFFORDABILITY, VALUE & EFFICIENCY (PAVE) ACT; ALL PROVISIONS OF THE DRAFT
More Efficient Tools to Realize Information for Consumers Act
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
H.R. 2113: PRESCRIPTION DRUG STAR ACT; ALL PROVISIONS OF THE BILL H.R. 2296: FAIR DRUG PRICING ACT OF 2019; ALL PROVISIONS OF THE BILL H.R. 2507: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2019; ALL PROVISIONS OF THE BILL S 474: STOPPING THE PHARMACEUTICAL INDUSTRY FROM KEEPING DRUGS EXPENSIVE (SPIKE) ACT OF 2019; ALL PROVISIONS OF THE BILL S. 1391 FAIR ACCOUNTABILITY AND INNOVATIVE RESEARCH (FAIR) DRUG PRICING ACT OF 2019; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING GENE THERAPY GENERAL DISCUSSIONS REGARDING THE ORPHAN DRUG ACT AND TAX CREDIT (NOT YET INTRODUCED) GENERAL DISCUSSIONS REGARDING PATIENT AFFORDABILITY, VALUE & EFFICIENCY (PAVE) ACT; ALL PROVISIONS OF THE DRAFT
More Efficient Tools to Realize Information for Consumers Act
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
H.R. 3: LOWER DRUG COSTS NOW ACT OF 2019; ALL PROVISIONS OF THE BILL H.R. 2069: SPIKE ACT; ALL PROVISIONS OF THE BILL H.R. 2296: MORE EFFICIENT TOOLS TO REALIZE INFORMATION FOR CONSUMERS ACT; ALL PROVISIONS OF THE BILL H.R. 2375: PRESERVE ACCESS TO AFFORDABLE GENERICS AND BIOSIMILARS ACT; ALL PROVISIONS OF THE BILL H.R. 2507: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2019; ALL PROVISIONS OF THE BILL H.R. 3235: ACCESS TO GENETIC COUNSELOR SERVICES ACT OF 2019; ALL PROVISIONS OF THE BILL H.R. 4439: CREATING HOPE REATHORIZATION ACT; ALL PROVISIONS OF THE BILL S. 2158: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2019; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING THE PRESCRIPTION DRUG PRICING REDUCTION ACT'S OUTCOMES BASED AGREEMENTS GENERAL DISCUSSIONS RELATED TO PHENYLKETONURIA (PKU) LOST TO FOLLOW UP
Preserve Access to Affordable Generics and Biosimilars Act
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
H.R. 3: LOWER DRUG COSTS NOW ACT OF 2019; ALL PROVISIONS OF THE BILL H.R. 2069: SPIKE ACT; ALL PROVISIONS OF THE BILL H.R. 2296: MORE EFFICIENT TOOLS TO REALIZE INFORMATION FOR CONSUMERS ACT; ALL PROVISIONS OF THE BILL H.R. 2375: PRESERVE ACCESS TO AFFORDABLE GENERICS AND BIOSIMILARS ACT; ALL PROVISIONS OF THE BILL H.R. 2507: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2019; ALL PROVISIONS OF THE BILL H.R. 3235: ACCESS TO GENETIC COUNSELOR SERVICES ACT OF 2019; ALL PROVISIONS OF THE BILL H.R. 4439: CREATING HOPE REATHORIZATION ACT; ALL PROVISIONS OF THE BILL S. 2158: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2019; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING THE PRESCRIPTION DRUG PRICING REDUCTION ACT'S OUTCOMES BASED AGREEMENTS GENERAL DISCUSSIONS RELATED TO PHENYLKETONURIA (PKU) LOST TO FOLLOW UP
Newborn Screening Saves Lives Reauthorization Act of 2019
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
H.R. 2507: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2019; ALL PROVISIONS OF THE BILL H.R. 4225: A BILL FOR THE RELIEF OF MARIA ISABEL BUESO BARRERA, ALBERTO BUESO MENDOZA, KARLA MARIA BARRERA DE BUESO AND ANA LUCIA BUESO BARRERA; PROVISIONS RELATED TO EXTEND DEFERRED PROGRAM H.R. 4667: BIOMEDICAL INNOVATION EXPANSION ACT OF 2019; PROVISIONS RELATED TO NATIONAL INSTITUTES OF HEALTH FUNDING FOR RARE DISEASE RESEARCH H.R. 4712: FAIRNESS IN ORPHAN DRUG EXCLUSIVITY ACT: ALL PROVISIONS OF THE BILL S 2158: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2019; ALL PROVISIONS OF THE BILL S 2612: A BILL FOR THE RELIEF OF MARIA ISABEL BUESO BARRERA, ALBERTO BUESO MENDOZA AND KARLA MARIA BARRERA DE BUESO; PROVISIONS RELATED TO EXTEND DEFERRED PROGRAM GENERAL DISCUSSIONS REGARDING GENE THERAPY GENERAL DISCUSSIONS REGARDING ORPHAN DRUG ACT GENERAL DISCUSSIONS REGARDING PHENYLKETONURIA (PKU) LOST TO FOLLOW UP GENERAL DISCUSSIONS REGARDING 21ST CENTURY CURES 2.0; PROVISIONS RELATED TO PATIENT ACCESS TO INNOVATION THERAPIES
Newborn Screening Saves Lives Reauthorization Act of 2019
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
H.R. 2113: PRESCRIPTION DRUG STAR ACT; ALL PROVISIONS OF THE BILL H.R. 2296: FAIR DRUG PRICING ACT OF 2019; ALL PROVISIONS OF THE BILL H.R. 2507: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2019; ALL PROVISIONS OF THE BILL S 474: STOPPING THE PHARMACEUTICAL INDUSTRY FROM KEEPING DRUGS EXPENSIVE (SPIKE) ACT OF 2019; ALL PROVISIONS OF THE BILL S. 1391 FAIR ACCOUNTABILITY AND INNOVATIVE RESEARCH (FAIR) DRUG PRICING ACT OF 2019; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING GENE THERAPY GENERAL DISCUSSIONS REGARDING THE ORPHAN DRUG ACT AND TAX CREDIT (NOT YET INTRODUCED) GENERAL DISCUSSIONS REGARDING PATIENT AFFORDABILITY, VALUE & EFFICIENCY (PAVE) ACT; ALL PROVISIONS OF THE DRAFT
Newborn Screening Saves Lives Reauthorization Act of 2019
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
H.R. 3: LOWER DRUG COSTS NOW ACT OF 2019; ALL PROVISIONS OF THE BILL H.R. 2069: SPIKE ACT; ALL PROVISIONS OF THE BILL H.R. 2296: MORE EFFICIENT TOOLS TO REALIZE INFORMATION FOR CONSUMERS ACT; ALL PROVISIONS OF THE BILL H.R. 2375: PRESERVE ACCESS TO AFFORDABLE GENERICS AND BIOSIMILARS ACT; ALL PROVISIONS OF THE BILL H.R. 2507: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2019; ALL PROVISIONS OF THE BILL H.R. 3235: ACCESS TO GENETIC COUNSELOR SERVICES ACT OF 2019; ALL PROVISIONS OF THE BILL H.R. 4439: CREATING HOPE REATHORIZATION ACT; ALL PROVISIONS OF THE BILL S. 2158: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2019; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING THE PRESCRIPTION DRUG PRICING REDUCTION ACT'S OUTCOMES BASED AGREEMENTS GENERAL DISCUSSIONS RELATED TO PHENYLKETONURIA (PKU) LOST TO FOLLOW UP
Elijah E. Cummings Lower Drug Costs Now Act
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
H.R. 3: LOWER DRUG COSTS NOW ACT OF 2019; ALL PROVISIONS OF THE BILL H.R. 2069: SPIKE ACT; ALL PROVISIONS OF THE BILL H.R. 2296: MORE EFFICIENT TOOLS TO REALIZE INFORMATION FOR CONSUMERS ACT; ALL PROVISIONS OF THE BILL H.R. 2375: PRESERVE ACCESS TO AFFORDABLE GENERICS AND BIOSIMILARS ACT; ALL PROVISIONS OF THE BILL H.R. 2507: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2019; ALL PROVISIONS OF THE BILL H.R. 3235: ACCESS TO GENETIC COUNSELOR SERVICES ACT OF 2019; ALL PROVISIONS OF THE BILL H.R. 4439: CREATING HOPE REATHORIZATION ACT; ALL PROVISIONS OF THE BILL S. 2158: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2019; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING THE PRESCRIPTION DRUG PRICING REDUCTION ACT'S OUTCOMES BASED AGREEMENTS GENERAL DISCUSSIONS RELATED TO PHENYLKETONURIA (PKU) LOST TO FOLLOW UP
Access to Genetic Counselor Services Act of 2019
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
H.R. 3: LOWER DRUG COSTS NOW ACT OF 2019; ALL PROVISIONS OF THE BILL H.R. 2069: SPIKE ACT; ALL PROVISIONS OF THE BILL H.R. 2296: MORE EFFICIENT TOOLS TO REALIZE INFORMATION FOR CONSUMERS ACT; ALL PROVISIONS OF THE BILL H.R. 2375: PRESERVE ACCESS TO AFFORDABLE GENERICS AND BIOSIMILARS ACT; ALL PROVISIONS OF THE BILL H.R. 2507: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2019; ALL PROVISIONS OF THE BILL H.R. 3235: ACCESS TO GENETIC COUNSELOR SERVICES ACT OF 2019; ALL PROVISIONS OF THE BILL H.R. 4439: CREATING HOPE REATHORIZATION ACT; ALL PROVISIONS OF THE BILL S. 2158: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2019; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING THE PRESCRIPTION DRUG PRICING REDUCTION ACT'S OUTCOMES BASED AGREEMENTS GENERAL DISCUSSIONS RELATED TO PHENYLKETONURIA (PKU) LOST TO FOLLOW UP
For the relief of Maria Isabel Bueso Barrera, Alberto Bueso Mendoza, Karla Maria Barrera De Bueso, and Ana Lucia Bueso Barrera.
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
H.R. 2507: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2019; ALL PROVISIONS OF THE BILL H.R. 4225: A BILL FOR THE RELIEF OF MARIA ISABEL BUESO BARRERA, ALBERTO BUESO MENDOZA, KARLA MARIA BARRERA DE BUESO AND ANA LUCIA BUESO BARRERA; PROVISIONS RELATED TO EXTEND DEFERRED PROGRAM H.R. 4667: BIOMEDICAL INNOVATION EXPANSION ACT OF 2019; PROVISIONS RELATED TO NATIONAL INSTITUTES OF HEALTH FUNDING FOR RARE DISEASE RESEARCH H.R. 4712: FAIRNESS IN ORPHAN DRUG EXCLUSIVITY ACT: ALL PROVISIONS OF THE BILL S 2158: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2019; ALL PROVISIONS OF THE BILL S 2612: A BILL FOR THE RELIEF OF MARIA ISABEL BUESO BARRERA, ALBERTO BUESO MENDOZA AND KARLA MARIA BARRERA DE BUESO; PROVISIONS RELATED TO EXTEND DEFERRED PROGRAM GENERAL DISCUSSIONS REGARDING GENE THERAPY GENERAL DISCUSSIONS REGARDING ORPHAN DRUG ACT GENERAL DISCUSSIONS REGARDING PHENYLKETONURIA (PKU) LOST TO FOLLOW UP GENERAL DISCUSSIONS REGARDING 21ST CENTURY CURES 2.0; PROVISIONS RELATED TO PATIENT ACCESS TO INNOVATION THERAPIES
Creating Hope Reauthorization Act
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
H.R. 3: LOWER DRUG COSTS NOW ACT OF 2019; ALL PROVISIONS OF THE BILL H.R. 2069: SPIKE ACT; ALL PROVISIONS OF THE BILL H.R. 2296: MORE EFFICIENT TOOLS TO REALIZE INFORMATION FOR CONSUMERS ACT; ALL PROVISIONS OF THE BILL H.R. 2375: PRESERVE ACCESS TO AFFORDABLE GENERICS AND BIOSIMILARS ACT; ALL PROVISIONS OF THE BILL H.R. 2507: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2019; ALL PROVISIONS OF THE BILL H.R. 3235: ACCESS TO GENETIC COUNSELOR SERVICES ACT OF 2019; ALL PROVISIONS OF THE BILL H.R. 4439: CREATING HOPE REATHORIZATION ACT; ALL PROVISIONS OF THE BILL S. 2158: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2019; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING THE PRESCRIPTION DRUG PRICING REDUCTION ACT'S OUTCOMES BASED AGREEMENTS GENERAL DISCUSSIONS RELATED TO PHENYLKETONURIA (PKU) LOST TO FOLLOW UP
Biomedical Innovation Expansion Act of 2019
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
H.R. 2507: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2019; ALL PROVISIONS OF THE BILL H.R. 4225: A BILL FOR THE RELIEF OF MARIA ISABEL BUESO BARRERA, ALBERTO BUESO MENDOZA, KARLA MARIA BARRERA DE BUESO AND ANA LUCIA BUESO BARRERA; PROVISIONS RELATED TO EXTEND DEFERRED PROGRAM H.R. 4667: BIOMEDICAL INNOVATION EXPANSION ACT OF 2019; PROVISIONS RELATED TO NATIONAL INSTITUTES OF HEALTH FUNDING FOR RARE DISEASE RESEARCH H.R. 4712: FAIRNESS IN ORPHAN DRUG EXCLUSIVITY ACT: ALL PROVISIONS OF THE BILL S 2158: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2019; ALL PROVISIONS OF THE BILL S 2612: A BILL FOR THE RELIEF OF MARIA ISABEL BUESO BARRERA, ALBERTO BUESO MENDOZA AND KARLA MARIA BARRERA DE BUESO; PROVISIONS RELATED TO EXTEND DEFERRED PROGRAM GENERAL DISCUSSIONS REGARDING GENE THERAPY GENERAL DISCUSSIONS REGARDING ORPHAN DRUG ACT GENERAL DISCUSSIONS REGARDING PHENYLKETONURIA (PKU) LOST TO FOLLOW UP GENERAL DISCUSSIONS REGARDING 21ST CENTURY CURES 2.0; PROVISIONS RELATED TO PATIENT ACCESS TO INNOVATION THERAPIES
Fairness in Orphan Drug Exclusivity Act
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
H.R. 2507: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2019; ALL PROVISIONS OF THE BILL H.R. 4225: A BILL FOR THE RELIEF OF MARIA ISABEL BUESO BARRERA, ALBERTO BUESO MENDOZA, KARLA MARIA BARRERA DE BUESO AND ANA LUCIA BUESO BARRERA; PROVISIONS RELATED TO EXTEND DEFERRED PROGRAM H.R. 4667: BIOMEDICAL INNOVATION EXPANSION ACT OF 2019; PROVISIONS RELATED TO NATIONAL INSTITUTES OF HEALTH FUNDING FOR RARE DISEASE RESEARCH H.R. 4712: FAIRNESS IN ORPHAN DRUG EXCLUSIVITY ACT: ALL PROVISIONS OF THE BILL S 2158: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2019; ALL PROVISIONS OF THE BILL S 2612: A BILL FOR THE RELIEF OF MARIA ISABEL BUESO BARRERA, ALBERTO BUESO MENDOZA AND KARLA MARIA BARRERA DE BUESO; PROVISIONS RELATED TO EXTEND DEFERRED PROGRAM GENERAL DISCUSSIONS REGARDING GENE THERAPY GENERAL DISCUSSIONS REGARDING ORPHAN DRUG ACT GENERAL DISCUSSIONS REGARDING PHENYLKETONURIA (PKU) LOST TO FOLLOW UP GENERAL DISCUSSIONS REGARDING 21ST CENTURY CURES 2.0; PROVISIONS RELATED TO PATIENT ACCESS TO INNOVATION THERAPIES
Affirming the importance of the Orphan Drug Act, celebrating the over 750 new orphan therapies approved since its creation, and recognizing the need to continue supporting research and development for rare diseases.
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
H.RES. 242: AFFIRMING THE IMPORTANCE OF THE ORPHAN DRUG ACT, CELEBRATING THE OVER 750 NEW ORPHAN THERAPIES APPROVED SINCE ITS CREATION, AND RECOGNIZING THE NEED TO CONTINUE SUPPORTING RESEARCH AND DEVELOPMENT FOR RARE DISEASE; ALL PROVISIONS OF THE RESOLUTION H.R. 1046: MEDICARE NEGOTIATION AND COMPETITIVE LICENSING ACT OF 2019; ALL PROVISION OF THE BILL S. 377: MEDICARE NEGOTIATION AND COMPETITIVE LICENSING ACT OF 2019; ALL PROVISION OF THE BILL GENERAL DISCUSSIONS REGARDING GENE THERAPY AND VALUE BASED CONTRACTING GENERAL DISCUSSIONS REGARDING NEWBORN SCREENING RE-AUTHORIZATION ACT GENERAL DISCUSSIONS REGARDING THE ORPHAN DRUG ACT GENERAL DISCUSSIONS REGARDING HEALTH CARE FINANCING
Fair Accountability and Innovative Research Drug Pricing Act of 2019
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
H.R. 2113: PRESCRIPTION DRUG STAR ACT; ALL PROVISIONS OF THE BILL H.R. 2296: FAIR DRUG PRICING ACT OF 2019; ALL PROVISIONS OF THE BILL H.R. 2507: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2019; ALL PROVISIONS OF THE BILL S 474: STOPPING THE PHARMACEUTICAL INDUSTRY FROM KEEPING DRUGS EXPENSIVE (SPIKE) ACT OF 2019; ALL PROVISIONS OF THE BILL S. 1391 FAIR ACCOUNTABILITY AND INNOVATIVE RESEARCH (FAIR) DRUG PRICING ACT OF 2019; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING GENE THERAPY GENERAL DISCUSSIONS REGARDING THE ORPHAN DRUG ACT AND TAX CREDIT (NOT YET INTRODUCED) GENERAL DISCUSSIONS REGARDING PATIENT AFFORDABILITY, VALUE & EFFICIENCY (PAVE) ACT; ALL PROVISIONS OF THE DRAFT
The Newborn Screening Saves Lives Reauthorization Act of 2019
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
H.R. 3: LOWER DRUG COSTS NOW ACT OF 2019; ALL PROVISIONS OF THE BILL H.R. 2069: SPIKE ACT; ALL PROVISIONS OF THE BILL H.R. 2296: MORE EFFICIENT TOOLS TO REALIZE INFORMATION FOR CONSUMERS ACT; ALL PROVISIONS OF THE BILL H.R. 2375: PRESERVE ACCESS TO AFFORDABLE GENERICS AND BIOSIMILARS ACT; ALL PROVISIONS OF THE BILL H.R. 2507: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2019; ALL PROVISIONS OF THE BILL H.R. 3235: ACCESS TO GENETIC COUNSELOR SERVICES ACT OF 2019; ALL PROVISIONS OF THE BILL H.R. 4439: CREATING HOPE REATHORIZATION ACT; ALL PROVISIONS OF THE BILL S. 2158: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2019; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING THE PRESCRIPTION DRUG PRICING REDUCTION ACT'S OUTCOMES BASED AGREEMENTS GENERAL DISCUSSIONS RELATED TO PHENYLKETONURIA (PKU) LOST TO FOLLOW UP
The Newborn Screening Saves Lives Reauthorization Act of 2019
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
H.R. 2507: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2019; ALL PROVISIONS OF THE BILL H.R. 4225: A BILL FOR THE RELIEF OF MARIA ISABEL BUESO BARRERA, ALBERTO BUESO MENDOZA, KARLA MARIA BARRERA DE BUESO AND ANA LUCIA BUESO BARRERA; PROVISIONS RELATED TO EXTEND DEFERRED PROGRAM H.R. 4667: BIOMEDICAL INNOVATION EXPANSION ACT OF 2019; PROVISIONS RELATED TO NATIONAL INSTITUTES OF HEALTH FUNDING FOR RARE DISEASE RESEARCH H.R. 4712: FAIRNESS IN ORPHAN DRUG EXCLUSIVITY ACT: ALL PROVISIONS OF THE BILL S 2158: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2019; ALL PROVISIONS OF THE BILL S 2612: A BILL FOR THE RELIEF OF MARIA ISABEL BUESO BARRERA, ALBERTO BUESO MENDOZA AND KARLA MARIA BARRERA DE BUESO; PROVISIONS RELATED TO EXTEND DEFERRED PROGRAM GENERAL DISCUSSIONS REGARDING GENE THERAPY GENERAL DISCUSSIONS REGARDING ORPHAN DRUG ACT GENERAL DISCUSSIONS REGARDING PHENYLKETONURIA (PKU) LOST TO FOLLOW UP GENERAL DISCUSSIONS REGARDING 21ST CENTURY CURES 2.0; PROVISIONS RELATED TO PATIENT ACCESS TO INNOVATION THERAPIES
A bill for the relief of Maria Isabel Bueso Barrera, Alberto Bueso Mendoza, and Karla Maria Barrera De Bueso.
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
H.R. 2507: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2019; ALL PROVISIONS OF THE BILL H.R. 4225: A BILL FOR THE RELIEF OF MARIA ISABEL BUESO BARRERA, ALBERTO BUESO MENDOZA, KARLA MARIA BARRERA DE BUESO AND ANA LUCIA BUESO BARRERA; PROVISIONS RELATED TO EXTEND DEFERRED PROGRAM H.R. 4667: BIOMEDICAL INNOVATION EXPANSION ACT OF 2019; PROVISIONS RELATED TO NATIONAL INSTITUTES OF HEALTH FUNDING FOR RARE DISEASE RESEARCH H.R. 4712: FAIRNESS IN ORPHAN DRUG EXCLUSIVITY ACT: ALL PROVISIONS OF THE BILL S 2158: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2019; ALL PROVISIONS OF THE BILL S 2612: A BILL FOR THE RELIEF OF MARIA ISABEL BUESO BARRERA, ALBERTO BUESO MENDOZA AND KARLA MARIA BARRERA DE BUESO; PROVISIONS RELATED TO EXTEND DEFERRED PROGRAM GENERAL DISCUSSIONS REGARDING GENE THERAPY GENERAL DISCUSSIONS REGARDING ORPHAN DRUG ACT GENERAL DISCUSSIONS REGARDING PHENYLKETONURIA (PKU) LOST TO FOLLOW UP GENERAL DISCUSSIONS REGARDING 21ST CENTURY CURES 2.0; PROVISIONS RELATED TO PATIENT ACCESS TO INNOVATION THERAPIES
Medicare Negotiation and Competitive Licensing Act of 2019
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
H.RES. 242: AFFIRMING THE IMPORTANCE OF THE ORPHAN DRUG ACT, CELEBRATING THE OVER 750 NEW ORPHAN THERAPIES APPROVED SINCE ITS CREATION, AND RECOGNIZING THE NEED TO CONTINUE SUPPORTING RESEARCH AND DEVELOPMENT FOR RARE DISEASE; ALL PROVISIONS OF THE RESOLUTION H.R. 1046: MEDICARE NEGOTIATION AND COMPETITIVE LICENSING ACT OF 2019; ALL PROVISION OF THE BILL S. 377: MEDICARE NEGOTIATION AND COMPETITIVE LICENSING ACT OF 2019; ALL PROVISION OF THE BILL GENERAL DISCUSSIONS REGARDING GENE THERAPY AND VALUE BASED CONTRACTING GENERAL DISCUSSIONS REGARDING NEWBORN SCREENING RE-AUTHORIZATION ACT GENERAL DISCUSSIONS REGARDING THE ORPHAN DRUG ACT GENERAL DISCUSSIONS REGARDING HEALTH CARE FINANCING
Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act of 2019
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
H.R. 2113: PRESCRIPTION DRUG STAR ACT; ALL PROVISIONS OF THE BILL H.R. 2296: FAIR DRUG PRICING ACT OF 2019; ALL PROVISIONS OF THE BILL H.R. 2507: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2019; ALL PROVISIONS OF THE BILL S 474: STOPPING THE PHARMACEUTICAL INDUSTRY FROM KEEPING DRUGS EXPENSIVE (SPIKE) ACT OF 2019; ALL PROVISIONS OF THE BILL S. 1391 FAIR ACCOUNTABILITY AND INNOVATIVE RESEARCH (FAIR) DRUG PRICING ACT OF 2019; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING GENE THERAPY GENERAL DISCUSSIONS REGARDING THE ORPHAN DRUG ACT AND TAX CREDIT (NOT YET INTRODUCED) GENERAL DISCUSSIONS REGARDING PATIENT AFFORDABILITY, VALUE & EFFICIENCY (PAVE) ACT; ALL PROVISIONS OF THE DRAFT
H.R. 5247: TRICKETT WENDLER, FRANK MONGIELLO, JORDAN MCLINN, AND MATTHEW BELLINA RIGHT TO TRY ACT OF 2018; ALL PROVISIONS OF THE BILL H.R. 5115: RARE dISEASE ADVANCEMENT, RESEARCH, AND EDUCATION (RARE) ACT OF 2018; ALL PROVISIONS OF THE BILL S. 204: TRICKETT WENDLER, FRANK MONGIELLO, JORDAN MCLINN, AND MATTHEW BELLINA RIGHT TO TRY ACT OF 2017; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING PRESERVATION OF ORPHAN DRUG ACT GENERAL DISCUSSIONS REGARDING FOOD AND DRUG ADMINISTRATION DISEASE EDUCATION GENERAL DISCUSSIONS REGARDING GENE THERAPY, RARE BRAIN DISORDER, FOOD AND DRUG ADMINISTRATION ADVISORY COMMITTEE MEETINGS AND PRESCRIPTION DRUG COST
Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2018
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
H.R. 5247: TRICKETT WENDLER, FRANK MONGIELLO, JORDAN MCLINN, AND MATTHEW BELLINA RIGHT TO TRY ACT OF 2018; ALL PROVISIONS OF THE BILL S. 204: TRICKETT WENDLER, FRANK MONGIELLO, JORDAN MCLINN, AND MATTHEW BELLINA RIGHT TO TRY ACT OF 2017; ALL PROVISIONS OF THE BILL ORPHAN DRUG ACT (NO BILL); PROVISIONS RELATED TO ORPHAN DRUG CREDIT, EXCLUSIVITY, DESIGNATION, AND EDUCATION
Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2018
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
H.R. 5247: TRICKETT WENDLER, FRANK MONGIELLO, JORDAN MCLINN, AND MATTHEW BELLINA RIGHT TO TRY ACT OF 2018; ALL PROVISIONS OF THE BILL H.R. 5115: RARE dISEASE ADVANCEMENT, RESEARCH, AND EDUCATION (RARE) ACT OF 2018; ALL PROVISIONS OF THE BILL S. 204: TRICKETT WENDLER, FRANK MONGIELLO, JORDAN MCLINN, AND MATTHEW BELLINA RIGHT TO TRY ACT OF 2017; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING PRESERVATION OF ORPHAN DRUG ACT GENERAL DISCUSSIONS REGARDING FOOD AND DRUG ADMINISTRATION DISEASE EDUCATION GENERAL DISCUSSIONS REGARDING GENE THERAPY, RARE BRAIN DISORDER, FOOD AND DRUG ADMINISTRATION ADVISORY COMMITTEE MEETINGS AND PRESCRIPTION DRUG COST
RaD Fund Act of 2018
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
H.R. 6801: RARE DISEASE FUND (RaD) ACT OF 2018; ALL PROVISION OF THE BILL GENERAL DISCUSSIONS REGARDING GENE THERAPY GENERAL DISCUSSIONS REGARDING PHENYLKETONURIA(PKU) EDUCATION AND OUTREACH GENERAL DISCUSSIONS REGARDING IMPACT OF FOOD AND DRUG ADMINISTRATION REORGANIZATION ON RARE DISEASE CLINICAL GENERAL DISCUSSIONS REGARDING AMERICAN PATIENTS FIRST: BLUEPRINT TO LOWER DRUG PRICES AND REDUCE OUT OF POCKET COSTS
Affirming the importance of the Orphan Drug Act, applauding its lifesaving contributions over its 35-year history, and recognizing the need to continue supporting research and development for rare diseases.
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
H.RES. 1154: AFFIRMING THE IMPORTANCE OF THE ORPHAN DRUG ACT, APPLAUDING ITS LIFESAVING CONTRIBUTIONS OVER ITS 35-YEAR HISTORY, AND RECOGNIZING THE NEED TO CONTINUE SUPPORTING RESEARCH AND DEVELOPMENT FOR RARE DISEASES; ALL PROVISIONS OF THE RESOLUTION GENERAL DISCUSSIONS REGARDING GENE THERAPY GENERAL DISCUSSIONS REGARDING PHENYLKETONURIA(PKU) EDUCATION AND OUTREACH GENERAL DISCUSSIONS REGARDING THE ORPHAN DRUG ACT GENERAL DISCUSSIONS REGARDING NEWBORN SCREENING GENERAL DISCUSSION REGARDING ADVANCE NOTICE OF PROPOSED RULE MAKING (ANPRM): INTERNATIONAL PRICING INDEX MODEL FOR MEDICARE PART B DRUGS GENERAL DISCUSSIONS REGARDING HEALTH EDUCATION
Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
H.R. 5247: TRICKETT WENDLER, FRANK MONGIELLO, JORDAN MCLINN, AND MATTHEW BELLINA RIGHT TO TRY ACT OF 2018; ALL PROVISIONS OF THE BILL H.R. 5115: RARE dISEASE ADVANCEMENT, RESEARCH, AND EDUCATION (RARE) ACT OF 2018; ALL PROVISIONS OF THE BILL S. 204: TRICKETT WENDLER, FRANK MONGIELLO, JORDAN MCLINN, AND MATTHEW BELLINA RIGHT TO TRY ACT OF 2017; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING PRESERVATION OF ORPHAN DRUG ACT GENERAL DISCUSSIONS REGARDING FOOD AND DRUG ADMINISTRATION DISEASE EDUCATION GENERAL DISCUSSIONS REGARDING GENE THERAPY, RARE BRAIN DISORDER, FOOD AND DRUG ADMINISTRATION ADVISORY COMMITTEE MEETINGS AND PRESCRIPTION DRUG COST
Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
H.R. 5247: TRICKETT WENDLER, FRANK MONGIELLO, JORDAN MCLINN, AND MATTHEW BELLINA RIGHT TO TRY ACT OF 2018; ALL PROVISIONS OF THE BILL S. 204: TRICKETT WENDLER, FRANK MONGIELLO, JORDAN MCLINN, AND MATTHEW BELLINA RIGHT TO TRY ACT OF 2017; ALL PROVISIONS OF THE BILL ORPHAN DRUG ACT (NO BILL); PROVISIONS RELATED TO ORPHAN DRUG CREDIT, EXCLUSIVITY, DESIGNATION, AND EDUCATION
An Act to provide for reconciliation pursuant to titles II and V of the concurrent resolution on the budget for fiscal year 2018.
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
H.R. 1: AN ACT TO PROVIDE FOR RECONCILIATION PURSUANT TO TITLES II AND V OF THE CONCURRENT RESOLUTION ON THE BUDGET FOR FISCAL YEAR 2018; PROVISIONS RELATED TO THE ORPHAN DRUG TAX CREDIT S. 204: TRICKETT WENDLER, FRANK MONGIELLO, JORDAN MCLINN, AND MATTHEW BELLINA RIGHT TO TRY ACT OF 2017; PROVISIONS RELATED TO EXPANDED ACCESS, USE OF OUTCOMES AND LANGUAGE
American Health Care Act of 2017
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
H.R. 1628: AMERICAN HEALTH CARE ACT OF 2017; PROVISIONS RELATED TO MEDICAID FUNDING. SPIKE ACT OF 2017 (DRAFT BILL): PROVISIONS RELATED TO PRESCRIPTION DRUG TRANSPARENCY. GENERAL DISCUSSION REGARDING PRODUCT LAUNCH. GENERAL DISCUSSION REGARDING THE ORPHAN DRUG ACT. GENERAL DISCUSSION REGARDING ACCELERATED APPROVAL FOR SOMATIC CELL GENE THERAPY.
American Health Care Act of 2017
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
H.R. 1628: AMERICAN HEALTH CARE ACT OF 2017; PROVISIONS RELATED TO MEDICAID FUNDING. SPIKE ACT OF 2017 (DRAFT BILL): PROVISIONS RELATED TO PRESCRIPTION DRUG TRANSPARENCY. GENERAL DISCUSSION REGARDING PRODUCT LAUNCH. GENERAL DISCUSSION REGARDING THE ORPHAN DRUG ACT. GENERAL DISCUSSION REGARDING ACCELERATED APPROVAL FOR SOMATIC CELL GENE THERAPY.
American Health Care Act of 2017
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
H.R.878: RIGHT TO TRY ACT OF 2017; PROVISIONS RELATED TO EXPANDED ACCESS AND USE OF OUTCOMES. H.R. 1628: AMERICAN HEALTH CARE ACT OF 2017 (SENATE DRAFT: BETTER CARE RECONCILIATION ACT OF 2017); PROVISIONS RELATED TO MEDICAID, BLOCK GRANTS AND WAIVERS FOR ESSENTIAL HEALTH BENEFITS. H.R. 2430: FDA REAUTHORIZATION ACT OF 2017; ALL PROVISIONS OF THE BILL. S. 204: TRICKETT WENDLER, FRANK MOGIELLO, JORDAN MCLINN AND MATTHEW BELLINA RIGHT TO TRY ACT OF 2017; PROVISIONS RELATED TO EXPANDED ACCESS, USE OF OUTCOMES AND LANGUAGE. S. 586: CORPORATE TAX DODGING PREVENTION ACT; PROVISIONS RELATED TO MEDICAID AND BLOCK GRANTS. S 934: FDA REAUTHORIZATION ACT OF 2017; PROVISIONS RELATED TO ORPHAN DRUGS AND EXPANDED ACCESS.
American Health Care Act of 2017
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
H.R. 1628: AMERICAN HEALTH CARE ACT OF 2017; ALL PROVISIONS OF THE BILL H.R. 2430: FDA REAUTHORIZATION ACT OF 2017; PROVISIONS RELATED TO ORPHAN DRUG ACT, RIGHT TO TRY AND RACE ACT S 934: FDA REAUTHORIZATION ACT OF 2017; PROVISIONS RELATED TO ORPHAN DRUG ACT, RIGHT TO TRY AND RACE ACT DRAFT BILL: BETTER CARE RECONCILIATION ACT; PROVISIONS RELATED TO MEDICAID AND WAIVERS FOR ESSENTIAL HEALTH BENEFITS DISCUSSIONS REGARDING THE ORPHAN DRUG ACT; PROVISIONS RELATED TO VALUE OF RARE DISEASE THERAPIES
FDA Reauthorization Act of 2017
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
H.R.878: RIGHT TO TRY ACT OF 2017; PROVISIONS RELATED TO EXPANDED ACCESS AND USE OF OUTCOMES. H.R. 1628: AMERICAN HEALTH CARE ACT OF 2017 (SENATE DRAFT: BETTER CARE RECONCILIATION ACT OF 2017); PROVISIONS RELATED TO MEDICAID, BLOCK GRANTS AND WAIVERS FOR ESSENTIAL HEALTH BENEFITS. H.R. 2430: FDA REAUTHORIZATION ACT OF 2017; ALL PROVISIONS OF THE BILL. S. 204: TRICKETT WENDLER, FRANK MOGIELLO, JORDAN MCLINN AND MATTHEW BELLINA RIGHT TO TRY ACT OF 2017; PROVISIONS RELATED TO EXPANDED ACCESS, USE OF OUTCOMES AND LANGUAGE. S. 586: CORPORATE TAX DODGING PREVENTION ACT; PROVISIONS RELATED TO MEDICAID AND BLOCK GRANTS. S 934: FDA REAUTHORIZATION ACT OF 2017; PROVISIONS RELATED TO ORPHAN DRUGS AND EXPANDED ACCESS.
FDA Reauthorization Act of 2017
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
H.R. 1628: AMERICAN HEALTH CARE ACT OF 2017; ALL PROVISIONS OF THE BILL H.R. 2430: FDA REAUTHORIZATION ACT OF 2017; PROVISIONS RELATED TO ORPHAN DRUG ACT, RIGHT TO TRY AND RACE ACT S 934: FDA REAUTHORIZATION ACT OF 2017; PROVISIONS RELATED TO ORPHAN DRUG ACT, RIGHT TO TRY AND RACE ACT DRAFT BILL: BETTER CARE RECONCILIATION ACT; PROVISIONS RELATED TO MEDICAID AND WAIVERS FOR ESSENTIAL HEALTH BENEFITS DISCUSSIONS REGARDING THE ORPHAN DRUG ACT; PROVISIONS RELATED TO VALUE OF RARE DISEASE THERAPIES
Right to Try Act of 2017
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
H.R.878: RIGHT TO TRY ACT OF 2017; PROVISIONS RELATED TO EXPANDED ACCESS AND USE OF OUTCOMES. H.R. 1628: AMERICAN HEALTH CARE ACT OF 2017 (SENATE DRAFT: BETTER CARE RECONCILIATION ACT OF 2017); PROVISIONS RELATED TO MEDICAID, BLOCK GRANTS AND WAIVERS FOR ESSENTIAL HEALTH BENEFITS. H.R. 2430: FDA REAUTHORIZATION ACT OF 2017; ALL PROVISIONS OF THE BILL. S. 204: TRICKETT WENDLER, FRANK MOGIELLO, JORDAN MCLINN AND MATTHEW BELLINA RIGHT TO TRY ACT OF 2017; PROVISIONS RELATED TO EXPANDED ACCESS, USE OF OUTCOMES AND LANGUAGE. S. 586: CORPORATE TAX DODGING PREVENTION ACT; PROVISIONS RELATED TO MEDICAID AND BLOCK GRANTS. S 934: FDA REAUTHORIZATION ACT OF 2017; PROVISIONS RELATED TO ORPHAN DRUGS AND EXPANDED ACCESS.
Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
H.R. 1: AN ACT TO PROVIDE FOR RECONCILIATION PURSUANT TO TITLES II AND V OF THE CONCURRENT RESOLUTION ON THE BUDGET FOR FISCAL YEAR 2018; PROVISIONS RELATED TO THE ORPHAN DRUG TAX CREDIT S. 204: TRICKETT WENDLER, FRANK MONGIELLO, JORDAN MCLINN, AND MATTHEW BELLINA RIGHT TO TRY ACT OF 2017; PROVISIONS RELATED TO EXPANDED ACCESS, USE OF OUTCOMES AND LANGUAGE
Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
H.R.878: RIGHT TO TRY ACT OF 2017; PROVISIONS RELATED TO EXPANDED ACCESS AND USE OF OUTCOMES. H.R. 1628: AMERICAN HEALTH CARE ACT OF 2017 (SENATE DRAFT: BETTER CARE RECONCILIATION ACT OF 2017); PROVISIONS RELATED TO MEDICAID, BLOCK GRANTS AND WAIVERS FOR ESSENTIAL HEALTH BENEFITS. H.R. 2430: FDA REAUTHORIZATION ACT OF 2017; ALL PROVISIONS OF THE BILL. S. 204: TRICKETT WENDLER, FRANK MOGIELLO, JORDAN MCLINN AND MATTHEW BELLINA RIGHT TO TRY ACT OF 2017; PROVISIONS RELATED TO EXPANDED ACCESS, USE OF OUTCOMES AND LANGUAGE. S. 586: CORPORATE TAX DODGING PREVENTION ACT; PROVISIONS RELATED TO MEDICAID AND BLOCK GRANTS. S 934: FDA REAUTHORIZATION ACT OF 2017; PROVISIONS RELATED TO ORPHAN DRUGS AND EXPANDED ACCESS.
Corporate Tax Dodging Prevention Act
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
H.R.878: RIGHT TO TRY ACT OF 2017; PROVISIONS RELATED TO EXPANDED ACCESS AND USE OF OUTCOMES. H.R. 1628: AMERICAN HEALTH CARE ACT OF 2017 (SENATE DRAFT: BETTER CARE RECONCILIATION ACT OF 2017); PROVISIONS RELATED TO MEDICAID, BLOCK GRANTS AND WAIVERS FOR ESSENTIAL HEALTH BENEFITS. H.R. 2430: FDA REAUTHORIZATION ACT OF 2017; ALL PROVISIONS OF THE BILL. S. 204: TRICKETT WENDLER, FRANK MOGIELLO, JORDAN MCLINN AND MATTHEW BELLINA RIGHT TO TRY ACT OF 2017; PROVISIONS RELATED TO EXPANDED ACCESS, USE OF OUTCOMES AND LANGUAGE. S. 586: CORPORATE TAX DODGING PREVENTION ACT; PROVISIONS RELATED TO MEDICAID AND BLOCK GRANTS. S 934: FDA REAUTHORIZATION ACT OF 2017; PROVISIONS RELATED TO ORPHAN DRUGS AND EXPANDED ACCESS.
FDA Reauthorization Act of 2017
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
H.R.878: RIGHT TO TRY ACT OF 2017; PROVISIONS RELATED TO EXPANDED ACCESS AND USE OF OUTCOMES. H.R. 1628: AMERICAN HEALTH CARE ACT OF 2017 (SENATE DRAFT: BETTER CARE RECONCILIATION ACT OF 2017); PROVISIONS RELATED TO MEDICAID, BLOCK GRANTS AND WAIVERS FOR ESSENTIAL HEALTH BENEFITS. H.R. 2430: FDA REAUTHORIZATION ACT OF 2017; ALL PROVISIONS OF THE BILL. S. 204: TRICKETT WENDLER, FRANK MOGIELLO, JORDAN MCLINN AND MATTHEW BELLINA RIGHT TO TRY ACT OF 2017; PROVISIONS RELATED TO EXPANDED ACCESS, USE OF OUTCOMES AND LANGUAGE. S. 586: CORPORATE TAX DODGING PREVENTION ACT; PROVISIONS RELATED TO MEDICAID AND BLOCK GRANTS. S 934: FDA REAUTHORIZATION ACT OF 2017; PROVISIONS RELATED TO ORPHAN DRUGS AND EXPANDED ACCESS.
FDA Reauthorization Act of 2017
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
H.R. 1628: AMERICAN HEALTH CARE ACT OF 2017; ALL PROVISIONS OF THE BILL H.R. 2430: FDA REAUTHORIZATION ACT OF 2017; PROVISIONS RELATED TO ORPHAN DRUG ACT, RIGHT TO TRY AND RACE ACT S 934: FDA REAUTHORIZATION ACT OF 2017; PROVISIONS RELATED TO ORPHAN DRUG ACT, RIGHT TO TRY AND RACE ACT DRAFT BILL: BETTER CARE RECONCILIATION ACT; PROVISIONS RELATED TO MEDICAID AND WAIVERS FOR ESSENTIAL HEALTH BENEFITS DISCUSSIONS REGARDING THE ORPHAN DRUG ACT; PROVISIONS RELATED TO VALUE OF RARE DISEASE THERAPIES
Advancing Hope Act of 2015
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
H.R. 6: 21ST CENTURY CURES ACT; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM H.R. 34: 21ST CENTURY CURES ACT; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM EXTENSION, REGENERATIVE MEDICINE, PATIENT EXPERIENCE DATA, AND REAL WORLD EVIDENCE DATA H.R. 971: ORPHAN PRODUCT EXTENSIONS NOW ACCELERATING CURES AND TREATMENTS ACT OF 2015; PROVISIONS RELATED TO PATENT EXTENSION H.R. 1537: ADVANCING HOPE ACT OF 2015; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM EXTENSION H.R. 3742: ACCESS TO MARKETPLACE INSURANCE ACT: PROVISIONS RELATED TO THIRD PARTY PREMIUM ASSISTANCE S 275: MEDICARE HOME INFUSION SITE OF CARE ACT OF 2015; PROVISIONS RELATED TO HOME INFUSION BENEFIT S 1421: ORPHAN PRODUCT EXTENSIONS NOW ACCELERATING CURES AND TREATMENTS ACT OF 2015; PROVISIONS RELATED TO PATENT EXTENSION S 1597: PATIENT-FOCUSED IMPACT ASSESSMENT ACT OF 2016; PROVISIONS RELATED TO PATIENT ENGAGEMENT AND FOOD AND DRUG ADMINISTRATION REQUIREMENTS S 1767: COMBINATION PRODUCT REGULATORY FAIRNESS ACT OF 2016; PROVISIONS RELATED TO COMBINATION PRODUCT REVIEW S 1878: ADVANCING HOPE ACT OF 2016; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM EXTENSION
Right to Try Act of 2015
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
H.R. 6: 21ST CENTURY CURES ACT; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM H.R. 3012: RIGHT TO TRY ACT OF 2015; PROVISIONS RELATED TO THE RIGHT TO TRY H.R. 3742: ACCESS TO MARKETPLACE INSURANCE ACT; PROVISIONS RELATED TO PATIENT ASSISTANCE S 1767: COMBINATION PRODUCT REGULATORY FAIRNESS ACT OF 2016; PROVISIONS RELATED TO REGULATION OF COMBINATION PRODUCTS S 1878: ADVANCING HOPE ACT OF 2016; ALL PROVISIONS OF THE BILL S 2912: TRICKETT WENDLER RIGHT TO TRY ACT OF 2016; PROVISIONS RELATED TO RIGHT TO TRY
21st Century Cures Act
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
H.R. 6: 21ST CENTURY CURES ACT; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM H.R. 34: 21ST CENTURY CURES ACT; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM EXTENSION, REGENERATIVE MEDICINE, PATIENT EXPERIENCE DATA, AND REAL WORLD EVIDENCE DATA H.R. 971: ORPHAN PRODUCT EXTENSIONS NOW ACCELERATING CURES AND TREATMENTS ACT OF 2015; PROVISIONS RELATED TO PATENT EXTENSION H.R. 1537: ADVANCING HOPE ACT OF 2015; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM EXTENSION H.R. 3742: ACCESS TO MARKETPLACE INSURANCE ACT: PROVISIONS RELATED TO THIRD PARTY PREMIUM ASSISTANCE S 275: MEDICARE HOME INFUSION SITE OF CARE ACT OF 2015; PROVISIONS RELATED TO HOME INFUSION BENEFIT S 1421: ORPHAN PRODUCT EXTENSIONS NOW ACCELERATING CURES AND TREATMENTS ACT OF 2015; PROVISIONS RELATED TO PATENT EXTENSION S 1597: PATIENT-FOCUSED IMPACT ASSESSMENT ACT OF 2016; PROVISIONS RELATED TO PATIENT ENGAGEMENT AND FOOD AND DRUG ADMINISTRATION REQUIREMENTS S 1767: COMBINATION PRODUCT REGULATORY FAIRNESS ACT OF 2016; PROVISIONS RELATED TO COMBINATION PRODUCT REVIEW S 1878: ADVANCING HOPE ACT OF 2016; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM EXTENSION
Access to Marketplace Insurance Act
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
H.R. 6: 21ST CENTURY CURES ACT; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM H.R. 34: 21ST CENTURY CURES ACT; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM EXTENSION, REGENERATIVE MEDICINE, PATIENT EXPERIENCE DATA, AND REAL WORLD EVIDENCE DATA H.R. 971: ORPHAN PRODUCT EXTENSIONS NOW ACCELERATING CURES AND TREATMENTS ACT OF 2015; PROVISIONS RELATED TO PATENT EXTENSION H.R. 1537: ADVANCING HOPE ACT OF 2015; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM EXTENSION H.R. 3742: ACCESS TO MARKETPLACE INSURANCE ACT: PROVISIONS RELATED TO THIRD PARTY PREMIUM ASSISTANCE S 275: MEDICARE HOME INFUSION SITE OF CARE ACT OF 2015; PROVISIONS RELATED TO HOME INFUSION BENEFIT S 1421: ORPHAN PRODUCT EXTENSIONS NOW ACCELERATING CURES AND TREATMENTS ACT OF 2015; PROVISIONS RELATED TO PATENT EXTENSION S 1597: PATIENT-FOCUSED IMPACT ASSESSMENT ACT OF 2016; PROVISIONS RELATED TO PATIENT ENGAGEMENT AND FOOD AND DRUG ADMINISTRATION REQUIREMENTS S 1767: COMBINATION PRODUCT REGULATORY FAIRNESS ACT OF 2016; PROVISIONS RELATED TO COMBINATION PRODUCT REVIEW S 1878: ADVANCING HOPE ACT OF 2016; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM EXTENSION
Access to Marketplace Insurance Act
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
H.R. 6: 21ST CENTURY CURES ACT; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM H.R. 3012: RIGHT TO TRY ACT OF 2015; PROVISIONS RELATED TO THE RIGHT TO TRY H.R. 3742: ACCESS TO MARKETPLACE INSURANCE ACT; PROVISIONS RELATED TO PATIENT ASSISTANCE S 1767: COMBINATION PRODUCT REGULATORY FAIRNESS ACT OF 2016; PROVISIONS RELATED TO REGULATION OF COMBINATION PRODUCTS S 1878: ADVANCING HOPE ACT OF 2016; ALL PROVISIONS OF THE BILL S 2912: TRICKETT WENDLER RIGHT TO TRY ACT OF 2016; PROVISIONS RELATED TO RIGHT TO TRY
21st Century Cures Act
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
H.R. 6: 21ST CENTURY CURES ACT; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM H.R. 34: 21ST CENTURY CURES ACT; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM EXTENSION, REGENERATIVE MEDICINE, PATIENT EXPERIENCE DATA, AND REAL WORLD EVIDENCE DATA H.R. 971: ORPHAN PRODUCT EXTENSIONS NOW ACCELERATING CURES AND TREATMENTS ACT OF 2015; PROVISIONS RELATED TO PATENT EXTENSION H.R. 1537: ADVANCING HOPE ACT OF 2015; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM EXTENSION H.R. 3742: ACCESS TO MARKETPLACE INSURANCE ACT: PROVISIONS RELATED TO THIRD PARTY PREMIUM ASSISTANCE S 275: MEDICARE HOME INFUSION SITE OF CARE ACT OF 2015; PROVISIONS RELATED TO HOME INFUSION BENEFIT S 1421: ORPHAN PRODUCT EXTENSIONS NOW ACCELERATING CURES AND TREATMENTS ACT OF 2015; PROVISIONS RELATED TO PATENT EXTENSION S 1597: PATIENT-FOCUSED IMPACT ASSESSMENT ACT OF 2016; PROVISIONS RELATED TO PATIENT ENGAGEMENT AND FOOD AND DRUG ADMINISTRATION REQUIREMENTS S 1767: COMBINATION PRODUCT REGULATORY FAIRNESS ACT OF 2016; PROVISIONS RELATED TO COMBINATION PRODUCT REVIEW S 1878: ADVANCING HOPE ACT OF 2016; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM EXTENSION
21st Century Cures Act
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
H.R. 6: 21ST CENTURY CURES ACT; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM S 1878: ADVANCING HOPE ACT OF 2016; ALL PROVISIONS OF THE BILL S 2030: ADVANCING TARGETED THERAPIES FOR RARE DISEASES ACT OF 2016; PROVISIONS RELATED TO PERSONALIZED MEDICINE GENERAL DISCUSSION REGARDING ORPHAN DRUG ACT PRESERVATION GENERAL DISCUSSION REGARDING THE SENATE INNOVATION ACT AND THE PRIORITY REVIEW VOUCHER PROGRAM
21st Century Cures Act
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
H.R. 6: 21ST CENTURY CURES ACT; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM H.R. 3012: RIGHT TO TRY ACT OF 2015; PROVISIONS RELATED TO THE RIGHT TO TRY H.R. 3742: ACCESS TO MARKETPLACE INSURANCE ACT; PROVISIONS RELATED TO PATIENT ASSISTANCE S 1767: COMBINATION PRODUCT REGULATORY FAIRNESS ACT OF 2016; PROVISIONS RELATED TO REGULATION OF COMBINATION PRODUCTS S 1878: ADVANCING HOPE ACT OF 2016; ALL PROVISIONS OF THE BILL S 2912: TRICKETT WENDLER RIGHT TO TRY ACT OF 2016; PROVISIONS RELATED TO RIGHT TO TRY
Orphan Product Extensions Now Accelerating Cures and Treatments Act of 2015
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
H.R. 6: 21ST CENTURY CURES ACT; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM H.R. 34: 21ST CENTURY CURES ACT; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM EXTENSION, REGENERATIVE MEDICINE, PATIENT EXPERIENCE DATA, AND REAL WORLD EVIDENCE DATA H.R. 971: ORPHAN PRODUCT EXTENSIONS NOW ACCELERATING CURES AND TREATMENTS ACT OF 2015; PROVISIONS RELATED TO PATENT EXTENSION H.R. 1537: ADVANCING HOPE ACT OF 2015; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM EXTENSION H.R. 3742: ACCESS TO MARKETPLACE INSURANCE ACT: PROVISIONS RELATED TO THIRD PARTY PREMIUM ASSISTANCE S 275: MEDICARE HOME INFUSION SITE OF CARE ACT OF 2015; PROVISIONS RELATED TO HOME INFUSION BENEFIT S 1421: ORPHAN PRODUCT EXTENSIONS NOW ACCELERATING CURES AND TREATMENTS ACT OF 2015; PROVISIONS RELATED TO PATENT EXTENSION S 1597: PATIENT-FOCUSED IMPACT ASSESSMENT ACT OF 2016; PROVISIONS RELATED TO PATIENT ENGAGEMENT AND FOOD AND DRUG ADMINISTRATION REQUIREMENTS S 1767: COMBINATION PRODUCT REGULATORY FAIRNESS ACT OF 2016; PROVISIONS RELATED TO COMBINATION PRODUCT REVIEW S 1878: ADVANCING HOPE ACT OF 2016; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM EXTENSION
Orphan Product Extensions Now Accelerating Cures and Treatments Act of 2015
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
H.R. 6: 21ST CENTURY CURES ACT; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM H.R. 34: 21ST CENTURY CURES ACT; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM EXTENSION, REGENERATIVE MEDICINE, PATIENT EXPERIENCE DATA, AND REAL WORLD EVIDENCE DATA H.R. 971: ORPHAN PRODUCT EXTENSIONS NOW ACCELERATING CURES AND TREATMENTS ACT OF 2015; PROVISIONS RELATED TO PATENT EXTENSION H.R. 1537: ADVANCING HOPE ACT OF 2015; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM EXTENSION H.R. 3742: ACCESS TO MARKETPLACE INSURANCE ACT: PROVISIONS RELATED TO THIRD PARTY PREMIUM ASSISTANCE S 275: MEDICARE HOME INFUSION SITE OF CARE ACT OF 2015; PROVISIONS RELATED TO HOME INFUSION BENEFIT S 1421: ORPHAN PRODUCT EXTENSIONS NOW ACCELERATING CURES AND TREATMENTS ACT OF 2015; PROVISIONS RELATED TO PATENT EXTENSION S 1597: PATIENT-FOCUSED IMPACT ASSESSMENT ACT OF 2016; PROVISIONS RELATED TO PATIENT ENGAGEMENT AND FOOD AND DRUG ADMINISTRATION REQUIREMENTS S 1767: COMBINATION PRODUCT REGULATORY FAIRNESS ACT OF 2016; PROVISIONS RELATED TO COMBINATION PRODUCT REVIEW S 1878: ADVANCING HOPE ACT OF 2016; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM EXTENSION
Patient-Focused Impact Assessment Act of 2016
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
H.R. 6: 21ST CENTURY CURES ACT; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM H.R. 34: 21ST CENTURY CURES ACT; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM EXTENSION, REGENERATIVE MEDICINE, PATIENT EXPERIENCE DATA, AND REAL WORLD EVIDENCE DATA H.R. 971: ORPHAN PRODUCT EXTENSIONS NOW ACCELERATING CURES AND TREATMENTS ACT OF 2015; PROVISIONS RELATED TO PATENT EXTENSION H.R. 1537: ADVANCING HOPE ACT OF 2015; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM EXTENSION H.R. 3742: ACCESS TO MARKETPLACE INSURANCE ACT: PROVISIONS RELATED TO THIRD PARTY PREMIUM ASSISTANCE S 275: MEDICARE HOME INFUSION SITE OF CARE ACT OF 2015; PROVISIONS RELATED TO HOME INFUSION BENEFIT S 1421: ORPHAN PRODUCT EXTENSIONS NOW ACCELERATING CURES AND TREATMENTS ACT OF 2015; PROVISIONS RELATED TO PATENT EXTENSION S 1597: PATIENT-FOCUSED IMPACT ASSESSMENT ACT OF 2016; PROVISIONS RELATED TO PATIENT ENGAGEMENT AND FOOD AND DRUG ADMINISTRATION REQUIREMENTS S 1767: COMBINATION PRODUCT REGULATORY FAIRNESS ACT OF 2016; PROVISIONS RELATED TO COMBINATION PRODUCT REVIEW S 1878: ADVANCING HOPE ACT OF 2016; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM EXTENSION
Combination Product Regulatory Fairness Act of 2016
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
H.R. 6: 21ST CENTURY CURES ACT; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM H.R. 3012: RIGHT TO TRY ACT OF 2015; PROVISIONS RELATED TO THE RIGHT TO TRY H.R. 3742: ACCESS TO MARKETPLACE INSURANCE ACT; PROVISIONS RELATED TO PATIENT ASSISTANCE S 1767: COMBINATION PRODUCT REGULATORY FAIRNESS ACT OF 2016; PROVISIONS RELATED TO REGULATION OF COMBINATION PRODUCTS S 1878: ADVANCING HOPE ACT OF 2016; ALL PROVISIONS OF THE BILL S 2912: TRICKETT WENDLER RIGHT TO TRY ACT OF 2016; PROVISIONS RELATED TO RIGHT TO TRY
Combination Product Regulatory Fairness Act of 2016
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
H.R. 6: 21ST CENTURY CURES ACT; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM H.R. 34: 21ST CENTURY CURES ACT; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM EXTENSION, REGENERATIVE MEDICINE, PATIENT EXPERIENCE DATA, AND REAL WORLD EVIDENCE DATA H.R. 971: ORPHAN PRODUCT EXTENSIONS NOW ACCELERATING CURES AND TREATMENTS ACT OF 2015; PROVISIONS RELATED TO PATENT EXTENSION H.R. 1537: ADVANCING HOPE ACT OF 2015; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM EXTENSION H.R. 3742: ACCESS TO MARKETPLACE INSURANCE ACT: PROVISIONS RELATED TO THIRD PARTY PREMIUM ASSISTANCE S 275: MEDICARE HOME INFUSION SITE OF CARE ACT OF 2015; PROVISIONS RELATED TO HOME INFUSION BENEFIT S 1421: ORPHAN PRODUCT EXTENSIONS NOW ACCELERATING CURES AND TREATMENTS ACT OF 2015; PROVISIONS RELATED TO PATENT EXTENSION S 1597: PATIENT-FOCUSED IMPACT ASSESSMENT ACT OF 2016; PROVISIONS RELATED TO PATIENT ENGAGEMENT AND FOOD AND DRUG ADMINISTRATION REQUIREMENTS S 1767: COMBINATION PRODUCT REGULATORY FAIRNESS ACT OF 2016; PROVISIONS RELATED TO COMBINATION PRODUCT REVIEW S 1878: ADVANCING HOPE ACT OF 2016; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM EXTENSION
Advancing Hope Act of 2016
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
S 1878: ADVANCING HOPE ACT OF 2016; ALL PROVISIONS OF THE BILL S 2030: ADVANCING TARGETED THERAPIES FOR RARE DISEASES ACT OF 2016; ALL PROVISIONS OF THE BILL
Advancing Hope Act of 2016
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
H.R. 6: 21ST CENTURY CURES ACT; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM H.R. 3012: RIGHT TO TRY ACT OF 2015; PROVISIONS RELATED TO THE RIGHT TO TRY H.R. 3742: ACCESS TO MARKETPLACE INSURANCE ACT; PROVISIONS RELATED TO PATIENT ASSISTANCE S 1767: COMBINATION PRODUCT REGULATORY FAIRNESS ACT OF 2016; PROVISIONS RELATED TO REGULATION OF COMBINATION PRODUCTS S 1878: ADVANCING HOPE ACT OF 2016; ALL PROVISIONS OF THE BILL S 2912: TRICKETT WENDLER RIGHT TO TRY ACT OF 2016; PROVISIONS RELATED TO RIGHT TO TRY
Advancing Hope Act of 2016
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
H.R. 6: 21ST CENTURY CURES ACT; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM S 1878: ADVANCING HOPE ACT OF 2016; ALL PROVISIONS OF THE BILL S 2030: ADVANCING TARGETED THERAPIES FOR RARE DISEASES ACT OF 2016; PROVISIONS RELATED TO PERSONALIZED MEDICINE GENERAL DISCUSSION REGARDING ORPHAN DRUG ACT PRESERVATION GENERAL DISCUSSION REGARDING THE SENATE INNOVATION ACT AND THE PRIORITY REVIEW VOUCHER PROGRAM
Advancing Hope Act of 2016
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
H.R. 6: 21ST CENTURY CURES ACT; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM H.R. 34: 21ST CENTURY CURES ACT; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM EXTENSION, REGENERATIVE MEDICINE, PATIENT EXPERIENCE DATA, AND REAL WORLD EVIDENCE DATA H.R. 971: ORPHAN PRODUCT EXTENSIONS NOW ACCELERATING CURES AND TREATMENTS ACT OF 2015; PROVISIONS RELATED TO PATENT EXTENSION H.R. 1537: ADVANCING HOPE ACT OF 2015; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM EXTENSION H.R. 3742: ACCESS TO MARKETPLACE INSURANCE ACT: PROVISIONS RELATED TO THIRD PARTY PREMIUM ASSISTANCE S 275: MEDICARE HOME INFUSION SITE OF CARE ACT OF 2015; PROVISIONS RELATED TO HOME INFUSION BENEFIT S 1421: ORPHAN PRODUCT EXTENSIONS NOW ACCELERATING CURES AND TREATMENTS ACT OF 2015; PROVISIONS RELATED TO PATENT EXTENSION S 1597: PATIENT-FOCUSED IMPACT ASSESSMENT ACT OF 2016; PROVISIONS RELATED TO PATIENT ENGAGEMENT AND FOOD AND DRUG ADMINISTRATION REQUIREMENTS S 1767: COMBINATION PRODUCT REGULATORY FAIRNESS ACT OF 2016; PROVISIONS RELATED TO COMBINATION PRODUCT REVIEW S 1878: ADVANCING HOPE ACT OF 2016; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM EXTENSION
Advancing Targeted Therapies for Rare Diseases Act of 2016
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
S 1878: ADVANCING HOPE ACT OF 2016; ALL PROVISIONS OF THE BILL S 2030: ADVANCING TARGETED THERAPIES FOR RARE DISEASES ACT OF 2016; ALL PROVISIONS OF THE BILL
Advancing Targeted Therapies for Rare Diseases Act of 2016
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
H.R. 6: 21ST CENTURY CURES ACT; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM S 1878: ADVANCING HOPE ACT OF 2016; ALL PROVISIONS OF THE BILL S 2030: ADVANCING TARGETED THERAPIES FOR RARE DISEASES ACT OF 2016; PROVISIONS RELATED TO PERSONALIZED MEDICINE GENERAL DISCUSSION REGARDING ORPHAN DRUG ACT PRESERVATION GENERAL DISCUSSION REGARDING THE SENATE INNOVATION ACT AND THE PRIORITY REVIEW VOUCHER PROGRAM
Medicare Home Infusion Site of Care Act of 2015
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
H.R. 6: 21ST CENTURY CURES ACT; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM H.R. 34: 21ST CENTURY CURES ACT; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM EXTENSION, REGENERATIVE MEDICINE, PATIENT EXPERIENCE DATA, AND REAL WORLD EVIDENCE DATA H.R. 971: ORPHAN PRODUCT EXTENSIONS NOW ACCELERATING CURES AND TREATMENTS ACT OF 2015; PROVISIONS RELATED TO PATENT EXTENSION H.R. 1537: ADVANCING HOPE ACT OF 2015; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM EXTENSION H.R. 3742: ACCESS TO MARKETPLACE INSURANCE ACT: PROVISIONS RELATED TO THIRD PARTY PREMIUM ASSISTANCE S 275: MEDICARE HOME INFUSION SITE OF CARE ACT OF 2015; PROVISIONS RELATED TO HOME INFUSION BENEFIT S 1421: ORPHAN PRODUCT EXTENSIONS NOW ACCELERATING CURES AND TREATMENTS ACT OF 2015; PROVISIONS RELATED TO PATENT EXTENSION S 1597: PATIENT-FOCUSED IMPACT ASSESSMENT ACT OF 2016; PROVISIONS RELATED TO PATIENT ENGAGEMENT AND FOOD AND DRUG ADMINISTRATION REQUIREMENTS S 1767: COMBINATION PRODUCT REGULATORY FAIRNESS ACT OF 2016; PROVISIONS RELATED TO COMBINATION PRODUCT REVIEW S 1878: ADVANCING HOPE ACT OF 2016; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM EXTENSION
Trickett Wendler Right to Try Act of 2016
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
H.R. 6: 21ST CENTURY CURES ACT; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM H.R. 3012: RIGHT TO TRY ACT OF 2015; PROVISIONS RELATED TO THE RIGHT TO TRY H.R. 3742: ACCESS TO MARKETPLACE INSURANCE ACT; PROVISIONS RELATED TO PATIENT ASSISTANCE S 1767: COMBINATION PRODUCT REGULATORY FAIRNESS ACT OF 2016; PROVISIONS RELATED TO REGULATION OF COMBINATION PRODUCTS S 1878: ADVANCING HOPE ACT OF 2016; ALL PROVISIONS OF THE BILL S 2912: TRICKETT WENDLER RIGHT TO TRY ACT OF 2016; PROVISIONS RELATED TO RIGHT TO TRY
Defending Public Safety Employees' Retirement Act
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 2146: DEFENDING PUBLIC SAFETY EMPLOYEES' RETIREMENT ACT - TITLE I: BIPARTISAN CONGRESSIONAL TRADE PRIORITIES AND ACCOUNTABILITY ACT OF 2015; PROVISIONS RELATED TO INTELLECTUAL PROPERTY
ACE Kids Act of 2015
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 6: 21ST CENTURY CURES ACT; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM AND PRECISION MEDICINE HR 546: ADVANCING CARE FOR EXCEPTIONAL KIDS(ACE)ACT OF 2015; ALL PROVISIONS OF THE BILL HR 971: ORPHAN PRODUCT EXTENSIONS NOW ACCELERATING CURES AND TREATMENTS ACT OF 2015; PROVISIONS RELATED TO ORPHAN DRUG TAX CREDIT EXCLUSIVITY S 320: MEDICAL INNOVATION ACT OF 2015; PROVISIONS RELATED TO PLATFORM TECHNOLOGIES AND RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM S 1421: ORPHAN PRODUCT EXTENSIONS NOW ACCELERATING CURES AND TREATMENTS ACT OF 2015; PROVISIONS RELATED TO ORPHAN DRUG TAX CREDIT EXCLUSIVITY S 1878: ADVANCING HOPE ACT OF 2015; ALL PROVISIONS OF THE BILL S 2030: ADVANCING TARGETED THERAPIES FOR RARE DISEASES ACT OF 2015; ALL PROVISIONS OF THE BILL
21st Century Cures Act
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 6: 21ST CENTURY CURES ACT; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM AND PRECISION MEDICINE HR 546: ADVANCING CARE FOR EXCEPTIONAL KIDS(ACE)ACT OF 2015; ALL PROVISIONS OF THE BILL HR 971: ORPHAN PRODUCT EXTENSIONS NOW ACCELERATING CURES AND TREATMENTS ACT OF 2015; PROVISIONS RELATED TO ORPHAN DRUG TAX CREDIT EXCLUSIVITY S 320: MEDICAL INNOVATION ACT OF 2015; PROVISIONS RELATED TO PLATFORM TECHNOLOGIES AND RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM S 1421: ORPHAN PRODUCT EXTENSIONS NOW ACCELERATING CURES AND TREATMENTS ACT OF 2015; PROVISIONS RELATED TO ORPHAN DRUG TAX CREDIT EXCLUSIVITY S 1878: ADVANCING HOPE ACT OF 2015; ALL PROVISIONS OF THE BILL S 2030: ADVANCING TARGETED THERAPIES FOR RARE DISEASES ACT OF 2015; ALL PROVISIONS OF THE BILL
21st Century Cures Act
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 6: 21ST CENTURY CURES ACT; PROVISIONS RELATED TO PEDIATRIC RARE DISEASE PRIORITY REVIEW VOUCHER REVIEW/APPROVAL PROTOCOLS HR 971: ORPHAN PRODUCT EXTENSIONS NOW ACCELERATING CURES AND TREATMENTS ACT OF 2015; PROVISIONS RELATED TO ORPHAN DRUG TAX CREDIT EXCLUSIVITY S 1421: ORPHAN PRODUCT EXTENSIONS NOW ACCELERATING CURES AND TREATMENTS ACT OF 2015; PROVISIONS RELATED TO ORPHAN DRUG TAX CREDIT EXCLUSIVITY S 1597: PATIENT-FOCUSED IMPACT ASSESSMENT ACT OF 2015; PROVISIONS RELATED TO PATIENT-FOCUSED DRUG DEVELOPMENT TOOLS
21st Century Cures Act
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 6: 21ST CENTURY CURES ACT; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM AND PRECISION MEDICINE S 320: MEDICAL INNOVATION ACT OF 2015; PROVISIONS RELATED TO PLATFORM TECHNOLOGIES AND RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM S 1878: ADVANCING HOPE ACT OF 2015; ALL PROVISIONS OF THE BILL S 2030: ADVANCING TARGETED THERAPIES FOR RARE DISEASES ACT OF 2015; ALL PROVISIONS OF THE BILL
Orphan Product Extensions Now Accelerating Cures and Treatments Act of 2015
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 6: 21ST CENTURY CURES ACT; PROVISIONS RELATED TO PEDIATRIC RARE DISEASE PRIORITY REVIEW VOUCHER REVIEW/APPROVAL PROTOCOLS HR 971: ORPHAN PRODUCT EXTENSIONS NOW ACCELERATING CURES AND TREATMENTS ACT OF 2015; PROVISIONS RELATED TO ORPHAN DRUG TAX CREDIT EXCLUSIVITY S 1421: ORPHAN PRODUCT EXTENSIONS NOW ACCELERATING CURES AND TREATMENTS ACT OF 2015; PROVISIONS RELATED TO ORPHAN DRUG TAX CREDIT EXCLUSIVITY S 1597: PATIENT-FOCUSED IMPACT ASSESSMENT ACT OF 2015; PROVISIONS RELATED TO PATIENT-FOCUSED DRUG DEVELOPMENT TOOLS
Orphan Product Extensions Now Accelerating Cures and Treatments Act of 2015
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 6: 21ST CENTURY CURES ACT; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM AND PRECISION MEDICINE HR 546: ADVANCING CARE FOR EXCEPTIONAL KIDS(ACE)ACT OF 2015; ALL PROVISIONS OF THE BILL HR 971: ORPHAN PRODUCT EXTENSIONS NOW ACCELERATING CURES AND TREATMENTS ACT OF 2015; PROVISIONS RELATED TO ORPHAN DRUG TAX CREDIT EXCLUSIVITY S 320: MEDICAL INNOVATION ACT OF 2015; PROVISIONS RELATED TO PLATFORM TECHNOLOGIES AND RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM S 1421: ORPHAN PRODUCT EXTENSIONS NOW ACCELERATING CURES AND TREATMENTS ACT OF 2015; PROVISIONS RELATED TO ORPHAN DRUG TAX CREDIT EXCLUSIVITY S 1878: ADVANCING HOPE ACT OF 2015; ALL PROVISIONS OF THE BILL S 2030: ADVANCING TARGETED THERAPIES FOR RARE DISEASES ACT OF 2015; ALL PROVISIONS OF THE BILL
Orphan Product Extensions Now Accelerating Cures and Treatments Act of 2015
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 6: 21ST CENTURY CURES ACT; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM AND PRECISION MEDICINE HR 546: ADVANCING CARE FOR EXCEPTIONAL KIDS(ACE)ACT OF 2015; ALL PROVISIONS OF THE BILL HR 971: ORPHAN PRODUCT EXTENSIONS NOW ACCELERATING CURES AND TREATMENTS ACT OF 2015; PROVISIONS RELATED TO ORPHAN DRUG TAX CREDIT EXCLUSIVITY S 320: MEDICAL INNOVATION ACT OF 2015; PROVISIONS RELATED TO PLATFORM TECHNOLOGIES AND RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM S 1421: ORPHAN PRODUCT EXTENSIONS NOW ACCELERATING CURES AND TREATMENTS ACT OF 2015; PROVISIONS RELATED TO ORPHAN DRUG TAX CREDIT EXCLUSIVITY S 1878: ADVANCING HOPE ACT OF 2015; ALL PROVISIONS OF THE BILL S 2030: ADVANCING TARGETED THERAPIES FOR RARE DISEASES ACT OF 2015; ALL PROVISIONS OF THE BILL
Orphan Product Extensions Now Accelerating Cures and Treatments Act of 2015
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 6: 21ST CENTURY CURES ACT; PROVISIONS RELATED TO PEDIATRIC RARE DISEASE PRIORITY REVIEW VOUCHER REVIEW/APPROVAL PROTOCOLS HR 971: ORPHAN PRODUCT EXTENSIONS NOW ACCELERATING CURES AND TREATMENTS ACT OF 2015; PROVISIONS RELATED TO ORPHAN DRUG TAX CREDIT EXCLUSIVITY S 1421: ORPHAN PRODUCT EXTENSIONS NOW ACCELERATING CURES AND TREATMENTS ACT OF 2015; PROVISIONS RELATED TO ORPHAN DRUG TAX CREDIT EXCLUSIVITY S 1597: PATIENT-FOCUSED IMPACT ASSESSMENT ACT OF 2015; PROVISIONS RELATED TO PATIENT-FOCUSED DRUG DEVELOPMENT TOOLS
Patient-Focused Impact Assessment Act of 2016
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 6: 21ST CENTURY CURES ACT; PROVISIONS RELATED TO PEDIATRIC RARE DISEASE PRIORITY REVIEW VOUCHER REVIEW/APPROVAL PROTOCOLS HR 971: ORPHAN PRODUCT EXTENSIONS NOW ACCELERATING CURES AND TREATMENTS ACT OF 2015; PROVISIONS RELATED TO ORPHAN DRUG TAX CREDIT EXCLUSIVITY S 1421: ORPHAN PRODUCT EXTENSIONS NOW ACCELERATING CURES AND TREATMENTS ACT OF 2015; PROVISIONS RELATED TO ORPHAN DRUG TAX CREDIT EXCLUSIVITY S 1597: PATIENT-FOCUSED IMPACT ASSESSMENT ACT OF 2015; PROVISIONS RELATED TO PATIENT-FOCUSED DRUG DEVELOPMENT TOOLS
Advancing Hope Act of 2016
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 6: 21ST CENTURY CURES ACT; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM AND PRECISION MEDICINE S 320: MEDICAL INNOVATION ACT OF 2015; PROVISIONS RELATED TO PLATFORM TECHNOLOGIES AND RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM S 1878: ADVANCING HOPE ACT OF 2015; ALL PROVISIONS OF THE BILL S 2030: ADVANCING TARGETED THERAPIES FOR RARE DISEASES ACT OF 2015; ALL PROVISIONS OF THE BILL
Advancing Hope Act of 2016
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 6: 21ST CENTURY CURES ACT; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM AND PRECISION MEDICINE HR 546: ADVANCING CARE FOR EXCEPTIONAL KIDS(ACE)ACT OF 2015; ALL PROVISIONS OF THE BILL HR 971: ORPHAN PRODUCT EXTENSIONS NOW ACCELERATING CURES AND TREATMENTS ACT OF 2015; PROVISIONS RELATED TO ORPHAN DRUG TAX CREDIT EXCLUSIVITY S 320: MEDICAL INNOVATION ACT OF 2015; PROVISIONS RELATED TO PLATFORM TECHNOLOGIES AND RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM S 1421: ORPHAN PRODUCT EXTENSIONS NOW ACCELERATING CURES AND TREATMENTS ACT OF 2015; PROVISIONS RELATED TO ORPHAN DRUG TAX CREDIT EXCLUSIVITY S 1878: ADVANCING HOPE ACT OF 2015; ALL PROVISIONS OF THE BILL S 2030: ADVANCING TARGETED THERAPIES FOR RARE DISEASES ACT OF 2015; ALL PROVISIONS OF THE BILL
Advancing Targeted Therapies for Rare Diseases Act of 2016
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 6: 21ST CENTURY CURES ACT; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM AND PRECISION MEDICINE S 320: MEDICAL INNOVATION ACT OF 2015; PROVISIONS RELATED TO PLATFORM TECHNOLOGIES AND RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM S 1878: ADVANCING HOPE ACT OF 2015; ALL PROVISIONS OF THE BILL S 2030: ADVANCING TARGETED THERAPIES FOR RARE DISEASES ACT OF 2015; ALL PROVISIONS OF THE BILL
Advancing Targeted Therapies for Rare Diseases Act of 2016
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 6: 21ST CENTURY CURES ACT; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM AND PRECISION MEDICINE HR 546: ADVANCING CARE FOR EXCEPTIONAL KIDS(ACE)ACT OF 2015; ALL PROVISIONS OF THE BILL HR 971: ORPHAN PRODUCT EXTENSIONS NOW ACCELERATING CURES AND TREATMENTS ACT OF 2015; PROVISIONS RELATED TO ORPHAN DRUG TAX CREDIT EXCLUSIVITY S 320: MEDICAL INNOVATION ACT OF 2015; PROVISIONS RELATED TO PLATFORM TECHNOLOGIES AND RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM S 1421: ORPHAN PRODUCT EXTENSIONS NOW ACCELERATING CURES AND TREATMENTS ACT OF 2015; PROVISIONS RELATED TO ORPHAN DRUG TAX CREDIT EXCLUSIVITY S 1878: ADVANCING HOPE ACT OF 2015; ALL PROVISIONS OF THE BILL S 2030: ADVANCING TARGETED THERAPIES FOR RARE DISEASES ACT OF 2015; ALL PROVISIONS OF THE BILL
Medical Innovation Act of 2015
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 6: 21ST CENTURY CURES ACT; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM AND PRECISION MEDICINE HR 546: ADVANCING CARE FOR EXCEPTIONAL KIDS(ACE)ACT OF 2015; ALL PROVISIONS OF THE BILL HR 971: ORPHAN PRODUCT EXTENSIONS NOW ACCELERATING CURES AND TREATMENTS ACT OF 2015; PROVISIONS RELATED TO ORPHAN DRUG TAX CREDIT EXCLUSIVITY S 320: MEDICAL INNOVATION ACT OF 2015; PROVISIONS RELATED TO PLATFORM TECHNOLOGIES AND RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM S 1421: ORPHAN PRODUCT EXTENSIONS NOW ACCELERATING CURES AND TREATMENTS ACT OF 2015; PROVISIONS RELATED TO ORPHAN DRUG TAX CREDIT EXCLUSIVITY S 1878: ADVANCING HOPE ACT OF 2015; ALL PROVISIONS OF THE BILL S 2030: ADVANCING TARGETED THERAPIES FOR RARE DISEASES ACT OF 2015; ALL PROVISIONS OF THE BILL
Medical Innovation Act of 2015
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 6: 21ST CENTURY CURES ACT; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM AND PRECISION MEDICINE S 320: MEDICAL INNOVATION ACT OF 2015; PROVISIONS RELATED TO PLATFORM TECHNOLOGIES AND RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM S 1878: ADVANCING HOPE ACT OF 2015; ALL PROVISIONS OF THE BILL S 2030: ADVANCING TARGETED THERAPIES FOR RARE DISEASES ACT OF 2015; ALL PROVISIONS OF THE BILL
2020 · first_quarter · Q1
H.R. 2507: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2019; ALL PROVISIONS OF THE BILL H.R. 6238: CAMERON'S LAW; ALL PROVISIONS OF THE BILL S 2158: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2019; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING PRESCRIPTION DRUG PRICING AND GENE THERAPY GENERAL DISCUSSIONS REGARDING ORPHAN DRUG ACT
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2019 · fourth_quarter · Q4
H.R. 2507: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2019; ALL PROVISIONS OF THE BILL H.R. 4225: A BILL FOR THE RELIEF OF MARIA ISABEL BUESO BARRERA, ALBERTO BUESO MENDOZA, KARLA MARIA BARRERA DE BUESO AND ANA LUCIA BUESO BARRERA; PROVISIONS RELATED TO EXTEND DEFERRED PROGRAM H.R. 4667: BIOMEDICAL INNOVATION EXPANSION ACT OF 2019; PROVISIONS RELATED TO NATIONAL INSTITUTES OF HEALTH FUNDING FOR RARE DISEASE RESEARCH H.R. 4712: FAIRNESS IN ORPHAN DRUG EXCLUSIVITY ACT: ALL PROVISIONS OF THE BILL S 2158: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2019; ALL PROVISIONS OF THE BILL S 2612: A BILL FOR THE RELIEF OF MARIA ISABEL BUESO BARRERA, ALBERTO BUESO MENDOZA AND KARLA MARIA BARRERA DE BUESO; PROVISIONS RELATED TO EXTEND DEFERRED PROGRAM GENERAL DISCUSSIONS REGARDING GENE THERAPY GENERAL DISCUSSIONS REGARDING ORPHAN DRUG ACT GENERAL DISCUSSIONS REGARDING PHENYLKETONURIA (PKU) LOST TO FOLLOW UP GENERAL DISCUSSIONS REGARDING 21ST CENTURY CURES 2.0; PROVISIONS RELATED TO PATIENT ACCESS TO INNOVATION THERAPIES
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2019 · third_quarter · Q3
H.R. 3: LOWER DRUG COSTS NOW ACT OF 2019; ALL PROVISIONS OF THE BILL H.R. 2069: SPIKE ACT; ALL PROVISIONS OF THE BILL H.R. 2296: MORE EFFICIENT TOOLS TO REALIZE INFORMATION FOR CONSUMERS ACT; ALL PROVISIONS OF THE BILL H.R. 2375: PRESERVE ACCESS TO AFFORDABLE GENERICS AND BIOSIMILARS ACT; ALL PROVISIONS OF THE BILL H.R. 2507: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2019; ALL PROVISIONS OF THE BILL H.R. 3235: ACCESS TO GENETIC COUNSELOR SERVICES ACT OF 2019; ALL PROVISIONS OF THE BILL H.R. 4439: CREATING HOPE REATHORIZATION ACT; ALL PROVISIONS OF THE BILL S. 2158: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2019; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING THE PRESCRIPTION DRUG PRICING REDUCTION ACT'S OUTCOMES BASED AGREEMENTS GENERAL DISCUSSIONS RELATED TO PHENYLKETONURIA (PKU) LOST TO FOLLOW UP
Filing targets: HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), SENATE, U.S. Immigration & Customs Enforcement (ICE)
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2019 · second_quarter · Q2
H.R. 2113: PRESCRIPTION DRUG STAR ACT; ALL PROVISIONS OF THE BILL H.R. 2296: FAIR DRUG PRICING ACT OF 2019; ALL PROVISIONS OF THE BILL H.R. 2507: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2019; ALL PROVISIONS OF THE BILL S 474: STOPPING THE PHARMACEUTICAL INDUSTRY FROM KEEPING DRUGS EXPENSIVE (SPIKE) ACT OF 2019; ALL PROVISIONS OF THE BILL S. 1391 FAIR ACCOUNTABILITY AND INNOVATIVE RESEARCH (FAIR) DRUG PRICING ACT OF 2019; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING GENE THERAPY GENERAL DISCUSSIONS REGARDING THE ORPHAN DRUG ACT AND TAX CREDIT (NOT YET INTRODUCED) GENERAL DISCUSSIONS REGARDING PATIENT AFFORDABILITY, VALUE & EFFICIENCY (PAVE) ACT; ALL PROVISIONS OF THE DRAFT
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2019 · first_quarter · Q1
H.RES. 242: AFFIRMING THE IMPORTANCE OF THE ORPHAN DRUG ACT, CELEBRATING THE OVER 750 NEW ORPHAN THERAPIES APPROVED SINCE ITS CREATION, AND RECOGNIZING THE NEED TO CONTINUE SUPPORTING RESEARCH AND DEVELOPMENT FOR RARE DISEASE; ALL PROVISIONS OF THE RESOLUTION H.R. 1046: MEDICARE NEGOTIATION AND COMPETITIVE LICENSING ACT OF 2019; ALL PROVISION OF THE BILL S. 377: MEDICARE NEGOTIATION AND COMPETITIVE LICENSING ACT OF 2019; ALL PROVISION OF THE BILL GENERAL DISCUSSIONS REGARDING GENE THERAPY AND VALUE BASED CONTRACTING GENERAL DISCUSSIONS REGARDING NEWBORN SCREENING RE-AUTHORIZATION ACT GENERAL DISCUSSIONS REGARDING THE ORPHAN DRUG ACT GENERAL DISCUSSIONS REGARDING HEALTH CARE FINANCING
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2018 · fourth_quarter · Q4
H.RES. 1154: AFFIRMING THE IMPORTANCE OF THE ORPHAN DRUG ACT, APPLAUDING ITS LIFESAVING CONTRIBUTIONS OVER ITS 35-YEAR HISTORY, AND RECOGNIZING THE NEED TO CONTINUE SUPPORTING RESEARCH AND DEVELOPMENT FOR RARE DISEASES; ALL PROVISIONS OF THE RESOLUTION GENERAL DISCUSSIONS REGARDING GENE THERAPY GENERAL DISCUSSIONS REGARDING PHENYLKETONURIA(PKU) EDUCATION AND OUTREACH GENERAL DISCUSSIONS REGARDING THE ORPHAN DRUG ACT GENERAL DISCUSSIONS REGARDING NEWBORN SCREENING GENERAL DISCUSSION REGARDING ADVANCE NOTICE OF PROPOSED RULE MAKING (ANPRM): INTERNATIONAL PRICING INDEX MODEL FOR MEDICARE PART B DRUGS GENERAL DISCUSSIONS REGARDING HEALTH EDUCATION
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2018 · third_quarter · Q3
H.R. 6801: RARE DISEASE FUND (RaD) ACT OF 2018; ALL PROVISION OF THE BILL GENERAL DISCUSSIONS REGARDING GENE THERAPY GENERAL DISCUSSIONS REGARDING PHENYLKETONURIA(PKU) EDUCATION AND OUTREACH GENERAL DISCUSSIONS REGARDING IMPACT OF FOOD AND DRUG ADMINISTRATION REORGANIZATION ON RARE DISEASE CLINICAL GENERAL DISCUSSIONS REGARDING AMERICAN PATIENTS FIRST: BLUEPRINT TO LOWER DRUG PRICES AND REDUCE OUT OF POCKET COSTS
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2018 · second_quarter · Q2
H.R. 5247: TRICKETT WENDLER, FRANK MONGIELLO, JORDAN MCLINN, AND MATTHEW BELLINA RIGHT TO TRY ACT OF 2018; ALL PROVISIONS OF THE BILL H.R. 5115: RARE dISEASE ADVANCEMENT, RESEARCH, AND EDUCATION (RARE) ACT OF 2018; ALL PROVISIONS OF THE BILL S. 204: TRICKETT WENDLER, FRANK MONGIELLO, JORDAN MCLINN, AND MATTHEW BELLINA RIGHT TO TRY ACT OF 2017; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING PRESERVATION OF ORPHAN DRUG ACT GENERAL DISCUSSIONS REGARDING FOOD AND DRUG ADMINISTRATION DISEASE EDUCATION GENERAL DISCUSSIONS REGARDING GENE THERAPY, RARE BRAIN DISORDER, FOOD AND DRUG ADMINISTRATION ADVISORY COMMITTEE MEETINGS AND PRESCRIPTION DRUG COST
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2018 · first_quarter · Q1
H.R. 5247: TRICKETT WENDLER, FRANK MONGIELLO, JORDAN MCLINN, AND MATTHEW BELLINA RIGHT TO TRY ACT OF 2018; ALL PROVISIONS OF THE BILL S. 204: TRICKETT WENDLER, FRANK MONGIELLO, JORDAN MCLINN, AND MATTHEW BELLINA RIGHT TO TRY ACT OF 2017; ALL PROVISIONS OF THE BILL ORPHAN DRUG ACT (NO BILL); PROVISIONS RELATED TO ORPHAN DRUG CREDIT, EXCLUSIVITY, DESIGNATION, AND EDUCATION
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2017 · fourth_quarter · Q4
H.R. 1: AN ACT TO PROVIDE FOR RECONCILIATION PURSUANT TO TITLES II AND V OF THE CONCURRENT RESOLUTION ON THE BUDGET FOR FISCAL YEAR 2018; PROVISIONS RELATED TO THE ORPHAN DRUG TAX CREDIT S. 204: TRICKETT WENDLER, FRANK MONGIELLO, JORDAN MCLINN, AND MATTHEW BELLINA RIGHT TO TRY ACT OF 2017; PROVISIONS RELATED TO EXPANDED ACCESS, USE OF OUTCOMES AND LANGUAGE
Filing targets: HOUSE OF REPRESENTATIVES, Office of the Vice President of the United States, SENATE
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2017 · third_quarter · Q3
H.R.878: RIGHT TO TRY ACT OF 2017; PROVISIONS RELATED TO EXPANDED ACCESS AND USE OF OUTCOMES. H.R. 1628: AMERICAN HEALTH CARE ACT OF 2017 (SENATE DRAFT: BETTER CARE RECONCILIATION ACT OF 2017); PROVISIONS RELATED TO MEDICAID, BLOCK GRANTS AND WAIVERS FOR ESSENTIAL HEALTH BENEFITS. H.R. 2430: FDA REAUTHORIZATION ACT OF 2017; ALL PROVISIONS OF THE BILL. S. 204: TRICKETT WENDLER, FRANK MOGIELLO, JORDAN MCLINN AND MATTHEW BELLINA RIGHT TO TRY ACT OF 2017; PROVISIONS RELATED TO EXPANDED ACCESS, USE OF OUTCOMES AND LANGUAGE. S. 586: CORPORATE TAX DODGING PREVENTION ACT; PROVISIONS RELATED TO MEDICAID AND BLOCK GRANTS. S 934: FDA REAUTHORIZATION ACT OF 2017; PROVISIONS RELATED TO ORPHAN DRUGS AND EXPANDED ACCESS.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2017 · second_quarter · Q2
H.R. 1628: AMERICAN HEALTH CARE ACT OF 2017; ALL PROVISIONS OF THE BILL H.R. 2430: FDA REAUTHORIZATION ACT OF 2017; PROVISIONS RELATED TO ORPHAN DRUG ACT, RIGHT TO TRY AND RACE ACT S 934: FDA REAUTHORIZATION ACT OF 2017; PROVISIONS RELATED TO ORPHAN DRUG ACT, RIGHT TO TRY AND RACE ACT DRAFT BILL: BETTER CARE RECONCILIATION ACT; PROVISIONS RELATED TO MEDICAID AND WAIVERS FOR ESSENTIAL HEALTH BENEFITS DISCUSSIONS REGARDING THE ORPHAN DRUG ACT; PROVISIONS RELATED TO VALUE OF RARE DISEASE THERAPIES
Filing targets: HOUSE OF REPRESENTATIVES, Office of the Vice President of the United States, SENATE
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2017 · first_quarter · 1A
H.R. 1628: AMERICAN HEALTH CARE ACT OF 2017; PROVISIONS RELATED TO MEDICAID FUNDING. SPIKE ACT OF 2017 (DRAFT BILL): PROVISIONS RELATED TO PRESCRIPTION DRUG TRANSPARENCY. GENERAL DISCUSSION REGARDING PRODUCT LAUNCH. GENERAL DISCUSSION REGARDING THE ORPHAN DRUG ACT. GENERAL DISCUSSION REGARDING ACCELERATED APPROVAL FOR SOMATIC CELL GENE THERAPY.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2017 · first_quarter · Q1
H.R. 1628: AMERICAN HEALTH CARE ACT OF 2017; PROVISIONS RELATED TO MEDICAID FUNDING. SPIKE ACT OF 2017 (DRAFT BILL): PROVISIONS RELATED TO PRESCRIPTION DRUG TRANSPARENCY. GENERAL DISCUSSION REGARDING PRODUCT LAUNCH. GENERAL DISCUSSION REGARDING THE ORPHAN DRUG ACT. GENERAL DISCUSSION REGARDING ACCELERATED APPROVAL FOR SOMATIC CELL GENE THERAPY.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2016 · fourth_quarter · Q4
H.R. 6: 21ST CENTURY CURES ACT; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM H.R. 34: 21ST CENTURY CURES ACT; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM EXTENSION, REGENERATIVE MEDICINE, PATIENT EXPERIENCE DATA, AND REAL WORLD EVIDENCE DATA H.R. 971: ORPHAN PRODUCT EXTENSIONS NOW ACCELERATING CURES AND TREATMENTS ACT OF 2015; PROVISIONS RELATED TO PATENT EXTENSION H.R. 1537: ADVANCING HOPE ACT OF 2015; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM EXTENSION H.R. 3742: ACCESS TO MARKETPLACE INSURANCE ACT: PROVISIONS RELATED TO THIRD PARTY PREMIUM ASSISTANCE S 275: MEDICARE HOME INFUSION SITE OF CARE ACT OF 2015; PROVISIONS RELATED TO HOME INFUSION BENEFIT S 1421: ORPHAN PRODUCT EXTENSIONS NOW ACCELERATING CURES AND TREATMENTS ACT OF 2015; PROVISIONS RELATED TO PATENT EXTENSION S 1597: PATIENT-FOCUSED IMPACT ASSESSMENT ACT OF 2016; PROVISIONS RELATED TO PATIENT ENGAGEMENT AND FOOD AND DRUG ADMINISTRATION REQUIREMENTS S 1767: COMBINATION PRODUCT REGULATORY FAIRNESS ACT OF 2016; PROVISIONS RELATED TO COMBINATION PRODUCT REVIEW S 1878: ADVANCING HOPE ACT OF 2016; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM EXTENSION
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2016 · third_quarter · Q3
H.R. 6: 21ST CENTURY CURES ACT; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM H.R. 3012: RIGHT TO TRY ACT OF 2015; PROVISIONS RELATED TO THE RIGHT TO TRY H.R. 3742: ACCESS TO MARKETPLACE INSURANCE ACT; PROVISIONS RELATED TO PATIENT ASSISTANCE S 1767: COMBINATION PRODUCT REGULATORY FAIRNESS ACT OF 2016; PROVISIONS RELATED TO REGULATION OF COMBINATION PRODUCTS S 1878: ADVANCING HOPE ACT OF 2016; ALL PROVISIONS OF THE BILL S 2912: TRICKETT WENDLER RIGHT TO TRY ACT OF 2016; PROVISIONS RELATED TO RIGHT TO TRY
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2016 · second_quarter · Q2
H.R. 6: 21ST CENTURY CURES ACT; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM S 1878: ADVANCING HOPE ACT OF 2016; ALL PROVISIONS OF THE BILL S 2030: ADVANCING TARGETED THERAPIES FOR RARE DISEASES ACT OF 2016; PROVISIONS RELATED TO PERSONALIZED MEDICINE GENERAL DISCUSSION REGARDING ORPHAN DRUG ACT PRESERVATION GENERAL DISCUSSION REGARDING THE SENATE INNOVATION ACT AND THE PRIORITY REVIEW VOUCHER PROGRAM
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2016 · first_quarter · Q1
S 1878: ADVANCING HOPE ACT OF 2016; ALL PROVISIONS OF THE BILL S 2030: ADVANCING TARGETED THERAPIES FOR RARE DISEASES ACT OF 2016; ALL PROVISIONS OF THE BILL
Filing targets: SENATE
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2015 · fourth_quarter · Q4
HR 6: 21ST CENTURY CURES ACT; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM AND PRECISION MEDICINE HR 546: ADVANCING CARE FOR EXCEPTIONAL KIDS(ACE)ACT OF 2015; ALL PROVISIONS OF THE BILL HR 971: ORPHAN PRODUCT EXTENSIONS NOW ACCELERATING CURES AND TREATMENTS ACT OF 2015; PROVISIONS RELATED TO ORPHAN DRUG TAX CREDIT EXCLUSIVITY S 320: MEDICAL INNOVATION ACT OF 2015; PROVISIONS RELATED TO PLATFORM TECHNOLOGIES AND RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM S 1421: ORPHAN PRODUCT EXTENSIONS NOW ACCELERATING CURES AND TREATMENTS ACT OF 2015; PROVISIONS RELATED TO ORPHAN DRUG TAX CREDIT EXCLUSIVITY S 1878: ADVANCING HOPE ACT OF 2015; ALL PROVISIONS OF THE BILL S 2030: ADVANCING TARGETED THERAPIES FOR RARE DISEASES ACT OF 2015; ALL PROVISIONS OF THE BILL
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2015 · third_quarter · Q3
HR 6: 21ST CENTURY CURES ACT; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM AND PRECISION MEDICINE S 320: MEDICAL INNOVATION ACT OF 2015; PROVISIONS RELATED TO PLATFORM TECHNOLOGIES AND RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM S 1878: ADVANCING HOPE ACT OF 2015; ALL PROVISIONS OF THE BILL S 2030: ADVANCING TARGETED THERAPIES FOR RARE DISEASES ACT OF 2015; ALL PROVISIONS OF THE BILL
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2015 · second_quarter · Q2
HR 2146: DEFENDING PUBLIC SAFETY EMPLOYEES' RETIREMENT ACT - TITLE I: BIPARTISAN CONGRESSIONAL TRADE PRIORITIES AND ACCOUNTABILITY ACT OF 2015; PROVISIONS RELATED TO INTELLECTUAL PROPERTY
HR 6: 21ST CENTURY CURES ACT; PROVISIONS RELATED TO PEDIATRIC RARE DISEASE PRIORITY REVIEW VOUCHER REVIEW/APPROVAL PROTOCOLS HR 971: ORPHAN PRODUCT EXTENSIONS NOW ACCELERATING CURES AND TREATMENTS ACT OF 2015; PROVISIONS RELATED TO ORPHAN DRUG TAX CREDIT EXCLUSIVITY S 1421: ORPHAN PRODUCT EXTENSIONS NOW ACCELERATING CURES AND TREATMENTS ACT OF 2015; PROVISIONS RELATED TO ORPHAN DRUG TAX CREDIT EXCLUSIVITY S 1597: PATIENT-FOCUSED IMPACT ASSESSMENT ACT OF 2015; PROVISIONS RELATED TO PATIENT-FOCUSED DRUG DEVELOPMENT TOOLS
Filing targets: HOUSE OF REPRESENTATIVES, SENATE